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8 I Chapter 1 
General Introduction 
A brief history of femoropopliteal bypass surgery 
Peripheral bypass surgery is a relatively young section of vascular surgery. Although 
atherosclerotic lesions were present in Egyptian mummies dating back 3500 years ago, we 
have long lacked the techniques to adequately treat occlusive arterial disease. Aneurysmal 
disease of the popliteal artery on the other hand has been treated since Antyllus (200AD) 
by applying ligatures to the entering and exiting arteries of the aneurysm and packing 
the cavity. This technique did not change until John Hunter (1728-1793) redesigned it 
by ligating the superficial femoral artery at Hunter's canal. This technique would remain 
again until Rudolph Matas developed the endoaneurysmorraphy in 18881 • 
Arterial reconstruction developed much slower. It was not before 1891 when Jassinowsky 
reported success in the suturing of arteries. In 1896 Jaboulay developed the end-to-end 
anastomosis in a carotid artery. His work was refined and expanded by Alexis Carrel. 
Carrel emphasized the importance of tissue handling and fine suture materials. Trauma 
to the intima was meticulously avoided when performing the anastomosis as he believed 
damage to the intima would lead to thrombosis. Arterial blood flow restoration was still 
not considered the main solution to peripheral arterial disease. In 1909 Leriche attempted 
to bypass a thrombosed artery using a vein graft, but failed as the distal limit of the 
thrombosis could not be identified. The discovery of X-rays in 1896 and consequential 
development of arteriographies by Barney Brooks in 1923 was an important step in the 
development of peripheral bypass surgery. Contemporaneously Jay McClean developed 
heparin (1916), which was successfully used in experimental arterial surgery afterwards. 
These discoveries led to an increase in popularity of the endarterectomy as performed 
by Jao Cid dos Santos in 1936. Unfortunately, the 
endarterectomy did not provide a full solution for 
longer occlusion of the SFA2. 
It was not until 1948 that the first femoral 
artery bypass was created. Jean Kuni in (Fig. 1) 
performed an autologous venous femoral bypass 
on a 54-year old man with gangrene of the foot. 
Figure 1. Rene Leriche with his students, including Mikael DeBakey, Rene Fontaine, Jean Cid dos Santos 
and Jean Kun/in. 
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The wounds healed postoperatively although the patient died a year after from massive 
stroke. The autologous venous surgical bypass has been the gold standard for long 
occlusion of the SFA ever since. 
Without a vein ... 
Autologous venous femoral bypasses remain the gold standard as their long-term 
patency rates exceed those of other bypasses. Primary patency rates of 75% at 5 years 
are yet to be attained by prosthetic bypasses. Unfortunately almost a third of the patients 
eligible for femoropopliteal bypass surgery do not have a suitable vein3 , which makes 
the use of prosthetic materials necessary. Preservation of the autologous saphenous vein 
for future bypass surgery, for example for coronary bypass surgery, is deemed obsolete4 • 
Several prosthetic bypasses (polytetrafluorethyleen (PTFE) , Dacron) and allografts (human 
umbilical vein (HUV)) have been developed during the last decades. 
HUV would, in theory, improve patency rates as it consisted of venous material. In below 
knee (BK) bypass surgery it improved primary patency compared to PTFE, but with a high 
incidence of graft dilatation (30%5). More recent studies do not endorse these results, but 
HUV is no longer available and taken off the commercial market because of transferable 
viral issues6• 
Dacron and PTFE have comparable primary and secondary patency rates7 •8 • Still in both 
above-knee (AK) as well as BK bypasses autologous vein conduits have significantly 
higher patency rates compared to PTFE9• The use of a vein cuff in a synthetic bypass does 
not seem to improve patency rates in AK bypasses. 
Recently, heparin-bonding of prosthetic bypasses has been introduced. This technique 
improved mid-term patency rates in both Dacron grafts (47% vs 35% 3-years primary 
patency10} and PTFE grafts (80% 2-year primary patency11 •12}. Limb salvage rates were also 
significantly improved (86% vs 74%). The Propaten trial compared Hb-PTFE grafts with 
standard PTFE grafts and reported primary patency rates of 87% and 80%, respectively. 
This difference was greatest in the femoropopliteal bypasses12 • With heparin-bonding 
synthetic PTFE and Dacron grafts have improved patency rates comparable to autologous 
venous conduits. 
Surgical bypasses are associated with a high complication rate (5-100%13•14} and a 
prolonged hospital stay (average of 5 days15}. The frail vascular population might benefit 
from a less invasive treatment strategy. Since 1994 the remote superficial femoral artery 
I 
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endarterectomy (RS FAE) is a minimal invasive alternative for the surgical bypass. It avoids 
synthetic materials and has a minimal invasive character as it is performed through a 
groin incision. In the REVAS trial (Remote Endarterectomy Versus Suprageniculate 
femoropopliteal bypass) primary patency rates at three years were 47%16. This is 
comparable to the synthetic grafts (56%), but inferior to the venous grafts (65%). The 
main confounding factor is early in-stent stenosis due to neointima hyperplasia (80% at 
1-year16). 
Endovascular treatment 
Over the past five decades interventional radiology has contributed 
a great deal to the treatment modalities of peripheral vascular 
disease. After Sven-Ivar Seldinger developed a safe method of 
puncturing the arteries in 19532 , developments followed rapidly. 
In 1964 Charles Dotter (Fig. 2) performed the first angioplasty 
on an 82-year old woman with gangrene of the foot. She fully 
recovered17 • These new minimal invasive techniques have 
conquered a place among the treatment modalities of peripheral 
arterial disease. In 2007 the Trans Atlantic interSociety Consensus 
(TASC II) recommended balloon angioplasty with or without stent 
Figure 2. 
Charles Dotter 
placement of short lesions of the superficial femoral artery (SFA) (TASC II A and TASC II 
B lesions18). In longer, more complex lesions (> 15cm) however, venous surgical bypass 
remained the gold standard. 
For longer lesions (mean 8 cm) primary patency rates following PTA of the SFA are 
reported to be as low as 33%-55% at 1-year follow-up1 9•20 • When comparing PTA of the 
SFA with optimal medical treatment, PTA shows better short term results (<6 months) but 
a 2-years followup both groups are comparable21, especially for longer lesions. 
The main limitation for PTA is the occurrence of restenosis due to neointimal hyperplasia. 
Drug eluting balloons (DEB) reduce this hyperplasia on the short term in the Thunder and 
FemPac trials (significant reduction of lumen loss at 6 months)22•23 • 
To reduce restenosis nitinol stent placement has been introduced. Early results of 
studies comparing PTA to PTA with stent placement show no significant difference in 
the overall primary patency rates, 36% vs 41 %24, but in longer lesions patency rates do 
improve significantly (12% vs 34%, p<0.05). The three major randomized trials are the 
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FAST, VIENNA and RESILIENT trials25-27• The FAST trial randomized 244 patients and their 
target lesion revascularisation rate (TLR) is higher in the PTA alone group (18% vs 15%). 
The RESILIENT trial report significant superior patency rates at 1 year for PTA with stent 
placement in short lesions (81 % vs 36%, P<0.0001) in a population of 204 patients. Finally 
the VIENNA trial is the smallest of the three (N=104), but they reported significantly lower 
restenosis rates after stenting. These studies show that use of stents increases patency 
rates after PT A. 
A further development of stents is the introduction of covered stents. The mechanical 
barrier of the cover prevents in-stent restenosis, reducing restenosis rates to edge stenos is 
only, as described recently by Fritschy et al28 . From 2000 several studies have shown 
primary patency rates between 74% and 83% at 12-months follow-up after treatment of 
long SFA lesions (mean length 22cm, range 4-40cm}29-32 • These results are comparable 
to synthetic surgical bypasses. Results are depended on device diameter, with smaller 
diameters (5mm) yielding poorer results (P=0.001). 
A randomized controlled trial comparing endografts with open surgical PTFE AK 
bypass33•34 confirms these results in long lesions of the SFA (26cm, +/-1 Scm}, describing 
comparable patency rates at 4 year follow up (59% and 58%, respectively). Secondary 
patency rates are 7 4% for the endograft group and 71 % for the surgical bypass group. 
Both show no significant difference. 
To further improve endograft patency rates and reduce edge stenosis drug-eluting and/ 
or drug-bonded stents have been developed. The advantage of these stents is the effect 
on neointimal hyperplasia and cell proliferation35• For paclitaxel-eluting stent grafts one­
year primary patency is as high as 86% for long lesions of the SFA36 • 
Recently heparin-bonding has been integrated with a PTFE covered stent (Viabahn). 
This might increase patency rates of this endograft even further, as heparin-bonding has 
increased patency rates of synthetic surgical bypasses12·36• 
Aim and outline of this thesis 
In this thesis we try to describe and clarify the place of endoluminal stentgrafts in the 
treatment algorithm for chronic long occlusive disease of the SFA by answering specific 
questions. 
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What are the current treatment modalities and how do endografts fit in this algorithm 
(Ch2, Ch8)? 
What are the patency rates of heparin bonded endografts for long lesions of the AFS 
(Ch3)? 
How can we further improve patency rates of endografts (Ch3)? 
How can we improve technical success rates for endograft placement (Ch7)? 
What is the outcome of patients after failure of the endograft (ChS & Ch6)? 
Does the overstenting of collaterals worsen patient clinical outcome after endograft 
failure (ChS)? 
Finally we have started a prospective randomized controlled trial comparing heparin­
bonded endografts with autologous venous surgical bypasses (SUPERB trial). The study 
protocol for this still including trial is described in Chapter 8. 
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Summary 
Treatment modal ities for extensive chronic occlusive d isease of the superficial 
femora l a rtery (SFA) have changed during the last decades. In this chapter we 
provide an  overview of current treatment modal ities for extensive chronic occlusive 
disease of the SFA. Although the autologous venous conduit is sti l l  considered the 
gold standard for treatment of long occlusive SFA lesions, endolumina l  therapy 
is ga in ing territory. Its min ima l  invasive character has great advantages in the 
frai l  vascu lar patient popu lation . Percutaneous trans luminal  angioplasty is first 
choice in short SFA lesions, but patency rates decrease with longer lesions. When 
percutaneous trans lumina l  angioplasty is combined with n itinol stent placement 
patency rates sign ificantly improve . Patency rates of percutaneous trans lumina l  
angioplasty combined with covered stents a re with in reach of patency rates of 
prosthetic surgica l bypasses. Drug-bonding in surg ica l PTFE bypasses increased 
patency rates sign ificantly. In the near futu re drug-e luting and drug-bonded devices 
might further increase resu lts of endovascu lar treatment. 
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Introduction 
Epidemiology 
Peripheral arterial disease (PAD) is a worldwide problem with a prevalence in the general 
population of 12-14%, affecting up to 20% of those persons over 70 years of age. 
The incidence of PAD increases with age from approximately 0.3% per year for men 
between 40-55 years of age, to 1 % in men older than 75 years1 . The risk factors for PAD 
are similar to those for coronary heart disease, and include smoking, diabetes mellitus 
(DM), hypertension, dyslipidemia and obesity. DM and smoking are particularly strong risk 
factors for the development of PAD. Smoking increases the risk of critical limb ischemia 
(CLI) 2.3 times compared to subjects who never smoked, while DM confers a 4.4 times 
increased risk of developing CU compared to the general population2 • PAD is a marker 
for systemic atherosclerotic disease. Persons with PAD, compared to those without, have 
four to five times the risk of dying of a cardiovascular event, resulting in a two to three 
times higher total mortality risk3 • 
Critical limb ischemia represents the extreme of this condition and may culminate to 
tissue loss, sometimes requi ring amputation of the affected limb. The prevalence of CLI 
in the general population is scarce. An European cross-sectional study estimated the 
prevalence to be 2,500 per million inhabitants4. This prevalence, however, is higher in the 
elderly population (age > 75 years). The progression of PAD to CU varies considerably 
in the published literature. One of the largest populations studied by Acquino et al 
followed 1244 patients with intermittent claudication ( IC) during 45 months. The authors 
combined the rate of developing an ischemic ulcer (23% over 10 years) with the rate 
of developing ischemic rest pain (30% over 20 years), which led to an annual rate of 
5.3% of claudicants progressing to CLl5 • Patients with IC and/or CU are known to have a 
low health-related quality of life (HROOL). Their HROOL is comparable to patients with 
cardiac disease or stroke. Besides diminished quality of life for individual patients, PAD 
also has a great impact on health care from a societal perspective. Few published data are 
available on the health care costs. An American study estimated the annual PAD-related 
costs from an administrative claims database. They found total mean annual PAD-related 
costs around $6000 per patient per year (PPPY). Hospital izations account for the largest 
part with 75% of the total annual PAD-related costs per PAD patient. PAD-related non­
coronary procedures average $729 PPPY (12.2% of total annual PAD-related costs), and 
I 
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PAD-related medications (including antihypertensive and lipid-lowering therapy) total 
$610 (10.2% of total annual costs)6 . Obviously, these results may differ between hospitals 
and regions. 
Classification 
In 2000 the Trans-Atlantic lnterSociety Consensus developed guidelines to provide an 
international consensus on the diagnosis and treatment of PAD (Trans-Atlantic Inter­
Society Consensus, TASC). With the development of new and improved treatment 
modalities the TASC workgroup updated their recommendations and revised the TASC 
I morphological stratification and treatment options in 20077 • For the classification of 
femoropopliteal lesions the TASC II guideline extended the possibilities for endovascular 
treatment modalities. TASC II A lesions are short occlusions (<Scm) or stenoses (<10cm) 
optimally treated with percutaneous transluminal angioplasty (PTA). TASC I I  B lesions 
consist of multiple short stenoses (<Scm) or single long stenosis (<1 Scm). These lesions 
are also optimally treated by PTA. TASC II C lesions are classified as multiple occlusions 
and/or stenoses totaling > 15cm in length. The TASC guideline recommends that these 
lesions are treated with surgical bypass. Endovascular modalities can be considered as 
secondary treatment after surgical intervention. 
TASC II D lesions are extensive (>20cm) chronic occlusions of the superficial femoral artery 
(SFA). Surgical bypass is recommended for this type of lesions. Recent developments 
of endovascular modalities have expanded treatment options for TASC II D lesions. 
Treatment strategies for these lesions are summarized in this chapter. 
Treatment moda l ities 
Conservative treatment 
Conservative treatment of PAD consists of lifestyle changing treatment (exercise and 
risk factor reduction) and optimal medical treatment. These regimes are the first line 
treatment in patients with extensive SFA disease without limb threatening symptoms, 
who are considered fit for exercise. Optimal medical treatment is recommended as a 
supplement for all patients independent of their symptoms at presentation. 
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Lifestyle changing treatment 
Although intermittent claudication is often the first symptom of systemic atherosclerotic 
disease and this population provides a potential opportunity for secondary prevention, 
life changing programs are not common practice in this population. The reduction 
of cardiovascular risk factors reduces morbidity and mortality due to coronary and 
cerebrovascular events, but also decreases the progression of peripheral atherosclerotic 
disease. Smoking cessation is the most clinically effective intervention for patients with 
atherosclerosis8 • Smokers with PAD have higher major amputation rate than non-smokers 
(6% vs 0%) and are more likely to undergo vascular reconstructions. Patients who quit 
smoking also showed a 36% relative risk (RR) reduction for all-cause mortality9 and a two­
fold increase of their 5-year survival rate 1 0. Special programs and patient motivation help 
successful smoking cessation. 
Exercise therapy can benefit patients with IC1 1 • Several theories exist about the underlying 
mechanisms. Exercise may improve the use of oxygen in the limb, reduce reliance on 
anaerobic metabolism, increase distribution of blood flow to the limb and decrease 
the viscosity of the blood1 1 -13 • A recent Cochrane review demonstrated that an exercise 
program was beneficial for patients with IC compared to non-exercised control groups1 4 . 
Exercise significantly improved maximum walking distance, pain free walking distance 
and maximum walking time. No improvement was seen in ankle brachia! index (ABI). 
Supervised walking training improved the walking distance more than unsupervised 
exercise therapy1 5 . 
Further risk factor reduction includes lipid lowering therapy and weight loss. Lipid 
lowering therapy through dietary measures offers only a small cardiovascular benefit. 
Statin treatment is discussed in the next chapter (Medical treatment). On the contrary, 
the loss of weight improves cholesterol levels , glucose levels and blood pressure 1 6, thus 
reducing cardiovascular risk. The reduction in weight also improves walking distance and 
enhances exercise program results. Patients with multilevel disease (i.e. expanding below 
knee) are at a higher risk of deteriorating during conservative treatment compared to 
patients with occlusive disease of the SFA only1 7  and therefore should be monitored more 
closely. 
Medical treatment 
Optimal medical management is recommended for all patients presenting with 
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atherosclerotic disease. Most commonly accepted is statin treatment unrelated to 
individual cholesterol levels. This lipid lowering strategy reduces the incidence of 
cardiovascular events in patients with PAD. It also showed a beneficial effect on the pain 
free and total walking distance, though there was no improvement of ABl1 8• Progression of 
atherosclerosis is thought to be halted by the use of statins. Two studies investigated this 
presumption. The St Thomas' trial19 showed significant reduction of disease progression 
on angiography. In contrast, the Probucol Quantitative Regression Swedish Trial (PORST) 
showed no difference with the placebo group20. 
Antiplatelet therapy is given to patients with PAD to reduce the risk of future 
cardiovascular events, but brings no improvement in clinical symptoms of PAD. Several 
newer medications are registered for the symptomatic treatment of patients without limb 
threatening symptoms, including buflomedil, naftidrofuryl and cilostazol. These agents 
offer a relatively small benefit in the maximum and pain free walking distance. There are 
no double blind, randomized controlled trials comparing these medications to a placebo 
group, thus there is not enough burden of proof to recommend it as standard treatment 
for PAD. Dietary supplements such as garlic, ginko bilboa, and vitamin E do not improve 
the clinical symptoms of PAD when compared to placebo. 
Surgical treatment 
Bypass surgery 
For long lesions of the SFA (TASC I I  D) bypass surgery is recommended as the fi rst choice 
of treatment in patients with Rutherford 3-67 • The first successful femoropopliteal bypass 
was performed in 1 948 by Jean Kunl in using an autologous vein graft. To date, this 
procedure is considered the gold standard for bypass surgery. Several prosthetic materials 
(polytetrafluorethylene (PTFE), Dacron) have been developed since then. More recently 
synthetic grafts have been expanded by heparin bonding. Below knee (BK) bypasses are 
known to have lower patency rates (49-79%) than above knee (AK) bypasses (60-90%). 
In both AK and BK bypasses autologous vein conduit has a significantly higher primary 
patency at five years compared to PTFE21 • Between Dacron and PTFE no significant 
differences in primary or secondary patency rates exist. One study showed a trend 
towards better patency rates for PTFE in the BK bypass after a follow-up 24 months22•23 • 
Above the knee there is no significant difference between PTFE or PTFE with vein cuff, 
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but in BK bypasses there is. Below the knee, the human umbilical vein (HUV) conduit also 
improved primary patency compared to PTFE. Older literature24, however, described a 
30% graft dilatation and aneurysm formation for HUV grafts. More recently these results 
could not be reproduced25 , but the graft is currently not commercially available anymore, 
because of transferable viral issues. 
Devine et al26 prospectively randomized 209 patients (30 with BK disease) between 
heparin bonded Dacron (HBD) grafts versus PTFE grafts for AK and BK bypass. HBD 
grafts improved the mid-term primary patency compared to PTFE in AK bypass (47% vs 
35% at 3 years), while n o  difference in patency rates were present in BK bypass. Limb 
salvage rates were 86% and 74%, respectively (P<0.025). Recently, Daenens et al27 
retrospectively compared heparin-bonded PTFE grafts (Hb-PTFE) with autologous vein 
grafts in  AK, BK and femorocrural (FC) bypasses. Two-year primary patency rates for the 
Hb-PTFE graft were 80%, 72% and 64% respectively, not significantly different from the 
autologous vein conduits. The Scandinavian Propaten Trial28 compared Hb-PTFE with 
standard PTFE grafts in femoropopiteal lesions. They also included patients scheduled for 
femoro-femoral cross over bypass. Primary patency rates for Hb-PTFE grafts were 86.6% 
compared to 79.9% in normal PTFE grafts (P=0.043). The risk reduction was most evident 
in femoropopliteal bypasses. 
Concerning postoperative medical treatment there is much heterogeneity in clinical 
practice. Different postoperative medical treatment is required for synthetic versus 
venous bypasses. Use of antiplatelet therapy improves synthetic graft 1-year patency. 
There was no difference in patients who received aspirin alone compared to aspirin with 
dipyridamol. Antithrombotic therapy (coumarines) improves graft patency for venous 
bypasses, despite higher risks of hemorrhagic complications29• The CASPAR trial showed 
that combining aspirin with clopidogrel did not improve limb or systemic outcomes in 
an overall patient population requiring a BK bypass (hazard ratio (HR) 0.98). A subgroup 
analysis suggested that in synthetic grafts clopidogrel plus aspirin shows a benefit (HR 
0.65, P=0.025)3°. 
Remote endarterectomy 
Since 1994 the remote superficial femoral artery endarterectomy (RSFAE) provides a 
minimal invasive surgical alternative to the surgical bypass. Through a groin incision a 
ring stripper is used to dissect the intima of the diseased segment,  followed by distal 
I 
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transection with a remote cutter. The transection zone is stented with a covered nitinol 
stent. Alternatively, the distal transection is performed surgically followed by Kunlin 
stitches. Gisbertz et al31  published the mid-term results of the REVAS trial (Figure 1). 
One-hundred and sixteen patients were randomized between RSFAE and AK bypass. 
The primary patency rates of the RSFAE at three years were inferior to the venous bypass 
(47% vs 65%), but comparable to the synthetic graft (56%). Primary assisted patency rates 
equal those of the venous bypass. Early restenosis rate (80% at 1 -year) of the RSFAE 
seems to be the confining factor due to aggressive neointimal hyperplasia. In the future 
the use of drug eluting stents (DES) or balloon cryoplasty might improve patency rates 
of this technique. Three-year limb salvage rates were comparable between RSFAE and 
bypass surgery {95%). Theoretically, RSFAE has fewer {early) postoperative complications 
compared to the surgical bypass due to its minimal invasive character. However, this could 
not be demonstrated in literature. Nevertheless, hospital stay was significantly shorter 
in RSFAE compared to surgical bypass. Obviously, RSFAE is an alternative for bypass 
surgery when there is no autologous vein available. The main advantage is the avoidance 
of prosthetic materials. 
Figure 1 .  Patient with invalidating claudication not responding to exercise therapy, with total SFA 
occlusion from the origin to P1  segment. No suitable vein was available, after which the de­
cision was made to perform remote superficial femoral  artery endarterectomy (A) through a 
groin incision. The Moll ring cutter was used (B) and at the transection site an Aspire stent 
was placed. (C). The endarterectomized specimen. AB/ improved from 0.54 before to 0. 91 
after the operation (Figures kindly provided by Dr. Jean-Paul de Vries, Nieuwegein). 
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Endovascular treatment 
Percutaneous transluminal angioplasty 
In past decades endovascu lar  techniques have advanced . For short lesions of the SFA 
(TASC A) and lesions of the i l iac artery PTA is considered the primary treatment7 • Although 
the incidence of restenosis fol lowing PTA of an i l iac artery is only 5-9% at 1 -year fol low-up, 
results a re more d isappointing in the SFA. Resu lts of angioplasty seem to depend on the 
length of the lesion .  For longer lesions (mean 8 cm) primary patency rates fol lowing PTA 
of the SFA are reported to be as low as 33%-55% at 1 -year  fol low-up32• I n  a retrospective 
review of 1 59 SFA lesions treated with PTA, Scott et a l33 showed primary patency rates 
of 55%, 43% and 35% at 1 2, 24 and 36-months, respectively. A review by Wilson et a l34 
comparing PTA of the SFA with optimal  medical treatment showed superior short term 
results for PTA (< 6 months), but at 2 years fol low-up no significant differences between 
the two groups were found .  This was true especia l ly for longer lesions (TASC II C/D). 
Table I summarizes PTA resu lts for long lesions of the SFA. I n  longer lesions the major 
l imitation of PTA is the occurrence of restenosis due to neointima l  hyperplasia .  To prevent 
this hyperplasia drug e luting ba l loons (DEB) have been developed . These ang ioplasty 
ba l loons are mostly coated with pacl itaxe l .  Their use in coronary a rtery d isease has  been 
shown in severa l randomized tria ls39 • An extrapolation to SFA disease in the Thunder 
and FemPac tria l s  with the use of DEB showed sign ificant reduction of l umen loss after 6 
months. Ta rget lesion revascu larisation was a lso sign ificantly reduced in the group treated 
with DEB40•41 • 
Study Zdanowski35 Minar32 Pokrajac36 van der Zaag37 Schillinger38 Total/ 
1 999 2000 2003 2004 2006 Average I 
# Patients 1 7  56 I 46 31 53 203 I 
I 
Lesion 




primary 0% 35% 47% 40% 37% 37% 
patency - - -
Table I. Patency rates of PTA of long SFA lesions. 
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Percutaneous transluminal angioplasty with bare stent 
As a possible solution to reduce the occurrence of restenosis after PTA, bare stents were 
implemented. Elastic recoil of the vessel wall could be prevented by the implantation of 
a metal stent. Initial results with these stents (Wall stents, Palmaz stents) failed to reduce 
restenosis rates and thus showed no improved patency rates (38% at 1-year, and 8% at 
three years). Secondary patency rates were improved to 89% and 55% with supplemental 
PTA42 . Still severe in stent restenosis occurred, diminishing patency rates. Besides the not 
significantly improved patency rates bare stent implantation introduced a new problem, 
i.e. stent fracture. Stent fractures are thought to be the result of the radial forces to which 
they are exposed within the SFA. 
Nitinol stents were introduced as a more flexible alternative, possibly reducing restenosis 
and stent fracture rates. Stent fractures were reduced to 7. 7% in long stented lesions (mean 
20.7cm)43 . Nguyen et al44 published the results of 824 primary endovascular procedu res 
comparing PTA alone versus PTA plus stenting. There was no difference in overall 5-year 
primary patency (36% vs 41 %, respectively). However, for TASC II C/D lesions stenting 
yielded significantly better primary patency rates (34% vs 12%, P<0.05). In literature one­
year primary patency rates vary between 80% for short lesions and 63% for longer lesions. 
The FAST trial45 randomized 244 patients between PTA alone and PTA with nitinol stent 
placement (mean lesion length 45mm). Their primary end point (i .e. binary restenosis) did 
not reach a statistical difference at 1 year follow-up. The target lesion revascularisation 
rate (TLR) was higher in the PTA group (18.3% vs 14.9%). The multi center RESILIENT trial46 
randomized 204 patients in a similar manner. At 1-year follow-up primary patency rates 
for the stent group were significantly better compared to PTA alone (8 1.3% vs 36.7%, 
P<0.0001 ). Freedom from TLR also significantly improved with the use of nitinol stent 
placement (87 .3% vs 45.1 %, P<0.0001 ). The third randomized trial included 104 patients 
(VIENNA trial38}. They reported significantly lower restenosis rates and better clinical 
outcome in the PTA with stent group compared to PTA alone. These three randomized 
trials (Table II) have shown that in longer lesions the use of nitinol stents is related to 
increased patency rates when compared to PTA only. 
Figure 2. A. Pre-operative proximal angiography in a 73-year-old man with CL/ Rutherford class 3, 
showing total SFA occlusion. Pre-operative AB/ was 0.64. B. Pre-operative distal re entry 
point on angiography of the same patient. C. Postoperative angiography after covered 
stentgraft placement in the same patient. Postoperative AB/ was 1 .0. D. Postoperative 
angiography showing distal re-entry point in same patient. 
FAST45 
# Patients 1 23 
Lesion length (cm) 4.5 
% occlusions 37% 
1 yr primary patency 68% 
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VIENNA38 Total/Average 
�6 26 




7 .3  
- - r32% 
70% 
Table II. Patency rates of PTA and stenting of long SFA lesions. 
Percutaneous transluminal angioplasty with endograft 
To further reduce the occurrence of in-stent restenosis covered stents were introduced 
(Figure 2) . The mechan ica l  barrier of the PTFE/Dacron cover around the n itinol stent would 
prevent in-stent stenosis. The first results using Dacron-covered stents were less promising. 
Almost 50% of the patients developed post-implantation syndrome (fever and persistent 
pain) and early restenosis rates (<30 days after the intervention) were 1 7%. The primary 
2-year patency rate was below 50%47 • A Scandinavian mu lticentre randomized tria l48 
planned to include 1 20 patients (60 in endograft groups and 60 in synthetic bypass g roup), 
but was terminated after an interim ana lysis of 45 patients. The 1 -year primary patency was 
48% for the endograft group compared to 95% for the PTFE open bypass group (P=0.02) . 
The worse outcome of the endograft group was expla ined by the authors by a lack in 
experience of the angioradiologists and a lso the maturity of the endolumina l  technique. 
Figure 2. (see left) 
I 
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In recent years endovascular modalities developed fast, leading to better results. In 2000 
Lammer et al49 published a multicenter study demonstrating 1-year primary and secondary 
patency rates of percutaneously placed endografts of 79% and 93% in 80 limbs. Saxon 
et al50 began to use endografts in a non-randomized manner to treat patients with a 
longer SFA stenosis (>5 cm) or occlusion (>3 cm) to determine long-term clinical outcome 
and patency. A total of 87 limbs were treated. Primary patency, primary assisted and 
secondary target vessel patency rates were 76%, 87% and 93% at 1-year follow-up and 
55%, 67% and 79% at 4-year follow-up. There was no significant difference in primary 
patency rates compared to the length of the lesion. However, results of the endograft 
were depended on device diameter, with smaller 5-mm devices yielding poorer results 
(P=0.001 ). Therefore, it is recommended that endografts are limited to patients with a re­
entry vessel with a diameter of at least 4.5 mm50. Clinical improvement was achieved in 
99% of the patients. This was maintained in 88.5% of the patients ,  with an average follow­
up of more than 28 months. Several other studies showed similar primary patency rates 
between 74% and 83% at 12-months follow-up after treatment of long SFA lesions (mean 
length 22cm , range 4-40cm)51 •52 . These results are comparable with primary patency rates 
as described for conventional surgical bypass using synthetic conduits. 
I n  2007 Kedora et al53 compared the efficacy of covered endografts to that of open 
surgical PTFE AK bypass. This single center prospective randomized trial included 100 
limbs (50 open surgical bypass, 50 endograft) with a mean follow-up of 28 months. 
It includes long lesions (mean length 25 cm) with an adequate mean diameter of 5.7 
mm. Postoperative complications were equal in both groups. Mean hospital stay was 
significantly shorter for the stent graft group (0. 9 days vs 3.1 days, P<0.001 ). The number 
of interventions were comparable in both groups after 12 months (14 in the endograft 
group vs 12 in the bypass group). One-year primary patency for the endograft group 
and open surgical bypass group was 73 .5% and 74.2%, respectively. Secondary patency 
rates were 83.7% for the endograft group and 83.9% for the surgical bypass group. Both 
showed no significant difference. At 48 months follow-up, primary patency rates for the 
endograft group and the open surgical bypass group were 59% and 58%, respectively. 
Secondary patency rates were 74% and 71%, respectively54 . These results underline the 
clinical utility of endograft placement as a treatment modality in SFA disease. The minimal 
invasive aspect of endoluminal stent graft also reduced the incidence of limb swelling and 
allows for rapid mobilization51 • 
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To further improve outcome of endograft placement it is essential to determine the 
underlying causes of loss of patency. The most common cause is edge stenosis55. 
Furthermore, when endoluminally treating long lesions of the SFA, care should be taken 
to have at least 1 cm of healthy vessel both proximally as distally of the lesion to ensure 
adequate re-entry possibil ities. There should also be a patent popliteal artery and an 
outflow of at least one open crural vessel. No severe calcification should be present56 • 
In a subgroup analysis of patients with these optimal conditions Fisher et al described 
improved primary and secondary patency rates of 80% and 91 %, respectively. Patency 
rates are summarized in Table Ill. 
Study Year # Patients Lesion length (cm) 
Lammer57 2000 
1 
80 1 3 .8 
Railo58 2001 
I 1 5  8 
Turicchia59 2003 
I 
1 6  
I 






67 1 1 4.3 
Hartung61 
I 
2005 34 1 0.8 
Panetta62 2005 
I 
41 I 30.4 
Zander63 2005 I 3 1  1 6 .6 
Fischer56 2006 
I 
48 I 1 0.7 
Kazemi64 2006 I 65 1 2  
Chopra65 2006 70 20 
Kedora53 2007 so 25.6 
Saxon50 2007 74 =-124,2 
Farraj66 2009 32 1 5 .4 
Fritschy55 
l:=_ 19
6 1 0.4 
[ Total 771 1 4.3 
Table Ill. Patency rates of PTA and covered stentgrafts 



















A possible downside of using covered stents might be the coverage of collateral arteries. 
Many believe that this wi l l  reduce l imb salvage or change the level of amputation after 
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failure of the graft. Literature shows no validation for this concern. After restenosis or 
occlusion of the endoluminal stent graft the majority of patients returns to baseline 
chronic limb ischemia. Failure of endovascular therapy does not seem to change the 
level of anastomosis of surgical bypass or amputation level. It also does not compromise 
options for surgical bypass53·54·67 • In patients with a technically difficult distal re-entry the 
recently described body floss technique can provide a quick way to minimize the stent 
length, thus sparing collaterals and future surgical options68 • Large collaterals may be 
saved by using a so-called hybrid technique including a covered and a distal bare stent. 
Drug-eluting and drug-bonded stents (DES, DBS) 
To reduce edge stenosis and increase patency drug-eluting and/or drug-bonded stents 
have been developed. The results from animal models demonstrated marked effects on 
neointimal hyperplasia and cell proliferation69. With heparin-bonded stents an adjunct 
theoretical advantage is the thromboresistance of the graft lumen, thereby preventing one 
of the principal causes of early failure, i .e.  deposition of thrombus on the luminal surface. 
Up to date no studies investigating heparin-bonded endografts have been published. 
Lensvelt et al recently described 56 lesions treated with heparin-bonded endografts for 
long occlusions of the SFA. At 1 year, primary patency was 75%, primary assisted patency 
82% and the secondary patency was 89%70 . 
The SIROCCO I and II trials7 1  compared Sirolimus-coated Cordis Self-Expanding stents 
with bare SMART stents in the treatment of TASC-C lesions of the SFA in a randomized 
fashion. Average lesion length was 8.3 cm. Restenosis rates were 22.9% and 21. 1 % 
respectively. No significant differences could be found between DES and bare SMART 
stents. For paclitaxel-eluting stent grafts Dake et al72 described the one-year results of 
900 lesions with long lesions of the SFA (mean length 99.5 mm). The primary patency 
rate was 86%. These results suggest promising developments for endoluminal treatment 
modalities in the future. 
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Concl usions 
With regard to conservative measures reducing cardiovascular risk factors it is anticipated 
to start with statin treatment despite cholesterol levels , to encourage weight loss and 
smoking cessation in all patients with PAD. Antiplatelet therapy should also be started at 
the onset of symptoms. Specifically patients who present with IC should start with exercise 
therapy, preferably supervised walking training. In patients with Rutherford category 
3-6 surgical therapy can be considered. When opting for surgical therapy autologous 
venous bypass is still the first choice. In patients were no vein is available, RSFAE could 
be considered before synthetic bypass. Minimal invasive endoluminal treatment is also a 
good treatment option, especially with frail patients. When endoluminally treating longer 
lesions of the SFA stenting is recommended, preferably with a covered nitinol stent. In the 
future drug-bonded stent grafts might improve endoluminal patency rates up to the level 
of venous bypass. Comparative studies , assessing both patency and quality of life, such 
as the SUrgical versus PERcutaneous Bypass (SuperB, NCT01220245) trial are therefore 
essential in defining the role of heparin-covered stent-grafts in the treatment algorithm of 
chronic occlusive SFA disease73. 
I 
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Abstract 
Objective 
To assess the 1 -year patency rates of heparin-bonded covered stents in  the 
treatment of ch ronic occlusive d isease of the superficia l femora l a rtery (SFA). 
Methods 
Al l patients treated with a heparin-bonded endograft between Apri l 2009 and 
October 201 0  for chron ic occlusive d isease of the SFA were prospectively gathered 
in a database and retrospectively analyzed. P rimary, primary-assisted and secondary 
patency rates, assessed by u ltrasound scann ing ,  were ana lyzed at 1 -year, as were 
the compl ication rates and mortal ity. 
Results 
A total of 56 l imbs were treated with a hepari n-bonded covered stent in 53 patients 
for chron ic ischemia Rutherford category 3 (n =36}, 4 (n =5}, 5 (n= 1 1 ) and 6 (n= 1 ) . 
Lesions were c lassified as TASC I I  B (n=9), C (n= 1 4) and D (n=33) and the mean 
treated lesion length was 1 8.5 ± 7 .7  cm . Postoperative compl ications occurred 
in 7 .5%, including hematoma (n= 1 }, edema (n= 1 }, pneumonia (n= 1 )  and u rinary 
retention (n= 1 } , and the 30-day mortality rate was 0%. The mean fol low-up was 41 3 
± 208 days. At 1 yea r, the primary patency was 76%, the primary-assisted patency 
82%, and the secondary patency 89%. The l imb salvage rate was 1 00%. 
Conclusions 
Heparin-bonded covered stents seem to provide a va l id a lternative to surg ica l 
treatment of long occlus ive lesions in the SFA. Randomized tria ls and long-term 
data are requ i red before considering the technique as a new standard of care .  
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Introduction 
Peripheral arterial disease (PAD) is a widespread problem with a prevalence of 3% to 
10%, increasing to 15% to 20% over the age of 70 years1 -3 • The prevalence of intermittent 
claudication is estimated 3% in patients aged 40 to 6% in patients aged 60 years4 •5 . One 
percent of patients with PAD will eventually develop critical limb ischemia annually. The 
Trans Atlantic lnterSociety Consensus (TASC) has given recommendations for treatment 
strategies, based on morphological stratification of the lesions5 • Surgery is considered the 
gold standard for lesions with a length of >15 cm. Endovascular alternatives and results , 
however, are evolving continuously. 
The introduction of nitinol stents has improved results of endovascular treatment of 
chronic occlusive lesions of the SFA. One-year primary patency rates have been reported 
between 63% and 80% in lesions with a length of 5cm to 11 cm6-8 • The major limitation 
of endovascular treatment is the occurrence of (in stent) restenosis due to intimal neo­
hyperplasia. To reduce the incidence of in stent restenosis covered stents have been 
introduced. We have recently shown that these may reduce restenosis to edge stenosis 
only9. Case series have shown 1-year primary patency rates between 44 and 93% for 
lesions from 8 cm up to 26cm10-12 • McOuade et al. have recently published the 4-year 
results of a randomized trial comparing an above-knee prosthetic femoropopliteal 
bypass with covered stents1 3 • There were no differences in primary or secondary patency 
rates between both treatment modalities and limb salvage rates were also comparable , 
indicating that covered stents may be a viable alternative for bypass surgery. The venous 
femoropopliteal bypass, however, is associated with higher patency rates, when compared 
to prosthetic bypasses1 4 • 
The introduction of the heparin-bonded technology has significantly improved patency 
rates of peripheral surgical bypasses15• 16• Since endograft failure is often due to acute 
thrombosis rather than in stent restenosis, the heparin-bonding technology has also been 
integrated with endografts. It is believed that the irreversible bonded heparin-molecules 
in the inner surface of the graft may prevent thrombosis, thus further increasing their 
performance. To date , no clinical studies have been published using heparin-bonded 
endografts. The aim of the present study was to assess the 1-year results of heparin­
bonded covered stents in the treatment of chronic occlusive disease of the SFA. 
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Patients and Methods 
Patients 
All patients treated with a heparin-bonded polytetrafluorethylene (ePTFE) covered 
stent between April 2009 and October 2010 in the Alysis Hospital, location Rijnstate in 
Arnhem and the lsala Clinics in Zwolle, The Netherlands were prospectively gathered 
in a database. Two dedicated vascular surgeons (MR and WF) and one interventional 
radiologist (JvO) performed all procedures. 
In all patients secondary risk prevention was performed according to the national 
guidelines and all patients with intermittent claudication were initially treated with walking 
exercise. Only those with unsuccessful exercise training were indicated for intervention. 
The indication for endovascular treatment was based on anatomical suitability and 
the preference of both the patient and surgeon. Generally, covered stents were used 
in lesions with a length of more than 15 cm, while bare metal stents or plain balloon 
angioplasty were used in shorter lesions. Anatomical suitability consisted of an adequate 
inflow without a flow-limiting stenosis in the aorto-iliac arteries, a patent popliteal artery 
above the P3 level with a luminal diameter of at least 4.2 mm and at least one patent 
crural vessel. 
Demographics, clinical status and medical history were noted and retrospectively 
reviewed. Procedural aspects and follow-up data were retrieved. Lesions were reviewed 
and scored according to the TASC II criteria5 • Additionally the lesion length, luminal vessel 
diameters and the number of patent run-off vessels were scored. 
Patients with a lesion length of < 5 cm were excluded from the analysis as were patients 
who had undergone a previous stent placement in the ipsilateral SFA or femoropopliteal 
bypass surgery. 
Follow-up consisted of clinical assessment, including physical examination, ankle-brachia I 
index (AB I) measurements, and duplex ultrasound scans at 1, 3, 6 and 12 months. The ABI 
was measured in a supine position using a Nicolet™ VasoGuard (CareFusion Corporation, 
San Diego, CA) or a Basic 3 (Atys Medical, Soucieu en Jarrest, France). Complications and 
additional treatments were registered in the hospital files. 
Definitions 
Risk factors were scored according to the Society for Vascular Surgery medical comorbidity 
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grading system. Restenosis was defined as a peak systolic velocity (PSV) ratio >2.5, as 
measured on ultrasound scanning. An occlusion was defined as absence of flow in the 
treated segment of the superficial femoral artery. Primary patency was defined as the 
absence of restenosis or occlusion in the target vessel. Primary-assisted patency was 
defined as patency achieved by secondary endovascular interventions to treat re-stenosis 
of the target vessel. Secondary patency was defined as patency achieved by all procedures 
aimed at recanalizing an occluded endograft, thereby preserving the endograft. Limb 
salvage was defined as the absence of an above ankle amputation. 
Treatment protocol 
Procedures were performed using antibiotic prophylaxis. The common femoral artery 
was approached either percutaneously or surgically, as preferred by the treating surgeon. 
When there was a concomitant lesion in the common or profunda femoral artery an 
endarterectomy was performed. Heparin (5000 IU) was administered. The diseased 
segment of the SFA was passed using a Terumo® wire (Terumo Medical Corporation , 
Elkton , MD) and a catheter, either endoluminal or subintimal and a re-entry was created 
distally. The segment was pre-dilated with a regular angioplasty balloon and the 
endografts were positioned from distal to proximal with minimal oversizing. The entire 
diseased segment was covered with endografts and endografts were postdilated with 
an angioplasty balloon with the same size as the endograft. Control angiography of the 
bypass and outflow vessels was performed routinely. In case of a percutaneous approach, 
the access was closed using a closure device (Angio-Seal™ , St Jude Medical, Minnesota, 
USA, or Proglide® , Abbott Vascular, Bruxelles, Belgium) or by manual compression. 
The used endograft was the heparin-bonded Viabahn Endoprosthesis (W.L. Gore & 
associates, Flagstaff, AZ, USA), which is a self-expanding helical nitinol stent covered with 
a heparin-bonded thin ePTFE tube. 
Postprocedural patients received statin treatment and dual anti-platelet inhibitors, unless 
oral anticoagulation was indicated for other reasons. 
Statistical Analysis 
Patient characteristics and characteristics of the treated lesions are presented as mean 
and standard deviation ,  unless otherwise stated. Patency rates were determined using the 
Kaplan Meier life-table method using PASW statistics version 18.0 (SPSS Inc. ,  Chicago, 
I 
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IL). Log-rank testing was used to determine possible differences in patency rates between 
different subgroup (i.e. different TASC II lesions, level of distal anastomosis, lesion length, 
diabetes mellitus, smoking, stent diameter, number of patent outflow vessels). A p-value 
< .05 was considered statistically significant. Data are presented as mean and standard 
deviation, unless otherwise stated. 
Results 
Patient population 
During the study period a total of 59 SFA's in 56 patients were scheduled for endovascular 
treatment, of which 56 SFA's were successfully treated (95%). In the remaining 3 patients 
the procedure was converted to an open femoropopliteal bypass because of the inability 
to recanalyze the diseased segment. The mean age was 69.6 ± 9.4 years and the 
male:female ratio was 40:13. Twenty-one patients (37.5%) were treated in the lsala Clinics 
in Zwolle and the remaining 35 (62.5%) in the Rijnstate hospital, Arnhem. 
Patient characteristics and risk factors are shown in Table 1. Four patients (7 . 1  %) had 
previously undergone an angioplasty of the SFA without stent placement, and 3 others 
(5.4%) had undergone an angioplasty with (n=2) or without (n=1) stent placement of the 
iliac artery. One patient already had a patent aorta-iliac bypass, and another patient had 
previously undergone an endarterectomy of the ipsilateral common femoral artery. Two 
patients (3.6%) had already undergone a minor amputation of the ipsilateral limb. 
The mean pre-procedural ABI was 0.49 ± 0.1 with a range of 0.19-0.74. Nine (16.1%) 
lesions were classified as TASC II B lesions, 14 (25%) as TASC II C lesions and the remaining 
33 (58.9%) were TASC II D lesions. The mean length of the lesions was 18.5 ± 7 .7cm. 















22 (41 ,6) 
31 (58,4) 
1 6  (30,2) 





History of cardiac d isease 
-
Neuro logica l  status 
Rena l  d isease 













> 1 0  years ago 
-
Stabi le AP, recent M l  
-
Non stabi le AP 
N (%) 
43 (8 1 , 1 )  
1 0  ( 1 8,9) 
41 (77 ,3) 
12 (22,7) 
I 33 (62,3) 
I � ,1 5 , 1 )  
- -
� 
9 (1 6,9) 
--




-� --- - -











I I  








1 ( 1 ,9) 
42 (79,2) 
8 ( 1 5 , 1 )  
3 (5 ,7) 
_ ---i 1 3  (24,5) 
--- -
40 (75 ,5) 
1 ( 1 ,9) 




-- ---- - -
I 5 (9,4) - - __ .__ --- - -
5 1 1  (20,8) -
1 (1 ,9) --
-
6 
Table 1 .  Patient characteristics and risk factors. ASA = American Society of Anesthesiologists. AP = 
angina pectoris, Ml = myocardial infarction, CVA = cerebrovascular accident, TIA = transient 
ischemic attack. 
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Anatomical character N (%) 
I 
P1 36 (64.3) 
-
Level of distal end of endograft P2 17 (30.3) 
- -
P3 3 (5.4) 
0 1 (1.8) 
I 1 5 (8.9) 
�umber of patent outflow vessels I I 2 11 (19.6) 
I 
3 39 (69.7) 
Lesion length (mm) I 1 85±77 
Luminal diameter superficial femoral artery (mm) 5 .4±1.1 
-- ---- -- -
+ t Luminal diameter popliteal artery (m� �46-075 
___J 
Table 2. Characteristics of the treated lesions. Data are presented as mean and standard deviation. P 1  
= popliteal artery cranial o f  the upper border of the patella. P2 = popliteal artery between the 
tibia plateau and upper border of the patella. P3 = popliteal artery below the tibia plateau 
Procedure 
Four patients were treated using local anesthesia only (7.5%), 26 were treated using 
spinal anesthetics (49.1 %) and the remaining 23 had general anesthetics (43.4%). The 
use of spinal or general anesthetics enabled a conversion to a hybrid approach or a 
surgical bypass in case of a technical failure within the same session. A percutaneous 
approach was used in 34 procedures (60.7%). In most of these cases access was acquired 
ultrasound-guided. Endografts were inserted with an exposed common femoral artery, 
as preferred by one of the surgeons, using a longitudinal incision in 11 patients (19.6%) 
and a concomitant endarterectomy of the communal femoral artery was performed in 
11 other patients (19.6%). An additional angioplasty of the iliac arteries, with bare metal 
stent placement in 2 of them, was performed in 5 patients in order to improve inflow and 
angioplasty of the popliteal artery was performed in 2 patients to improve outflow. Three 
patients underwent a necrotectomy and a planned minor amputation was performed in 
2 patients. In one patient a bilateral procedure was combined with the treatment of an 
abdominal aortic aneurysm using EVAR. Postoperatively, one patient was treated with 
continuous thrombolytic therapy, because of thrombosis of the crural arteries that already 
existed before the intervention. This was also the only patient who stayed in the medium 
care unit during the 2 days of receiving thrombolytic therapy. 
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In 16 cases (28.6%) one endograft was used, in 18 procedures (32.1 %) two endografts 
were used and in the remaining 22 cases (39.3%) three endografts were used. In 3 cases 
(5.4%) the used diameter of the endograft was 5mm, in 45 patients (80.4%) 6mm, in 7 
patients (12.5%) 7mm, and in 1 patient (1.7%) 8mm. 
One procedure was complicated by a dissection of the popliteal artery that was treated 
in the same session with an additional endograft. Postoperative complications occurred 
in 4 out of 53 patients (7 .5%). One patient had a hematoma at the puncture site that was 
treated conservatively. One patient sustained urine retention conservatively treated with 
a urinary catheter for 24 hours. One patient developed pneumonia and was treated with 
antibiotics. One patient had an edema, without signs of deep venous thrombosis on 
duplex ultrasound. The swelling and redness, probably due to reperfusion, disappeared 
during the first postoperative month. The 30-day mortality rate was 0%. 
Patients were admitted to the hospital for a mean of 3.0 ± 2.6 days. Most patients were 
admitted the day before the intervention. Patients who underwent a percutaneous 
procedure had a mean length of stay of 2.4 ± 1.2 days and patients with an open approach 
were admitted for 3.6 ±2.5 days. The mean postoperative ABI was 1.00, with a range of 
0.74-1.17. 
Postoperatively, 37 (69.8%) patients were treated with the combination of acetylsalicylic 
acid 80 mg and clopidogrel 75 mg, 8 patients (15.1 %) received acetylsalicylic acid 80 
mg with dipyridamol 400 mg and 4 (7 .5%) patients were treated by acetylsalicylic acid 
80 mg only. Four (7 .5%) patients were treated by coumarin derivates because of other 
indications. All patients were treated with statins. 
Clinical outcome 
All but one patient clinically improved after placement of the endograft(s) (Fig. 1). 
The median Rutherford improved from category 3 (range 3-6) pre-operatively to 
category O (range 0-4) postoperatively (P<0.001 ). There was one patient that did not 
improve clinically having an early endograft failure and she was treated with a surgical 
femoropopliteal bypass. The subset of patients that were treated for critical limb ischemia 
(n=18) had all improved. Sixteen patients (88.9%) improved from critical ischemia to 
claudication (Rutherford 1 to 3) and the others were asymptomatic. At one-year follow-up 
the freedom from target lesion revascularization was 92.6%. 
II 
48 \ Chapter 3 
Preprocedural Rutherford category 
29 
Postprocedural Rutherford category 
D 
D 
··· .. \[] 
··...... 2 •� nc=14 
D 
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Figure 1. Individual changes in the Rutherford categories before and after the procedure. 
Patency 
The mean fo l low-up was 4 1 3 ± 208 days. The one-year primary patency was 76.2%, the 
1 -yea r primary-assisted patency was 8 1 .7% and the secondary patency rate was 89.0% 
(Fig. 2). During fol low-up, no major a mputations were performed. 
A un ivariate ana lysis of risk factors, commonly associated with fai lu re ,  showed no 
sign ificant difference between subgroups, as defined in the statistica l ana lysis (Table 3) .  
The n umber of endografts used seemed to have a n  effect on the patency rate, a lthough 
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not statistica l ly sign ificant (P= .097) .  The use of 3 endografts decreased the primary 
patency rate with respectively 28% and 24% when compared with the use of 1 and 2 
endografts (Fig. 3) .  Moreover, patients with a s ingle vessel run off (n=S) tended to have 
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Figure 2. Kaplan-Meier survival curve showing primary patency, primary-assisted patency and secondary 
patency of the heparin-bonded endografts. 
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Risk Factor 
TASC-2 Classification 
Level distal a nastomosis 
Lesion length 
Diabetes Mel l itus 
Smoking 
Endograft diameter 
Number of used endografts 
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Table 3. Primary patency rates of the heparin-bonded endografts in relation to risk factors for failure. 
TASC = Trans Atlantic lnterSociety Consensus. P1 = popliteal artery cranial of the upper bor­
der of the patella. P2 = popliteal artery between the tibia plateau and upper border of the 
patella. P3 = popliteal artery below the tibia plateau 
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Figure 3 .  Kaplan-Meier survival curve showing primary patency i n  relation t o  the number of endo­
grafts used. 
Outcome of failures 
During follow-up the endograft failed in six patients (10. 1 %). In all but one patient the 
Rutherford category at time of failure was similar or lower when compared to the pre­
operative Rutherford category. The other patient went from Rutherford category 3 to 
category 4. 
In two patients, with a pre-procedural Rutherford classification of respectively 3 and 4, the 
occlusion was found during routine duplex surveillance without having clinical symptoms. 
The other four patients returned with symptoms and were al l  initially treated by chemical 
I 
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thrombolysis. In one patient the endograft then remained patent for another nine months, 
before it finally failed. This patient was treated with a below-knee ePTFE bypass due to 
the absence of usable vein conduit. In the other three patients thrombolysis failed and 
they were treated with a venous above-knee femoropopliteal bypass. The distal runoff 
did not change after failure of the endograft, when compared to the pre-operative state. 
Discussion 
The present study shows the results of the first prospective cohort of patients treated 
in our centers with a heparin-bonded covered stent for chronic occlusive disease of the 
SFA. Based on our data, we conclude that the use of heparin-bonded covered stents for 
this indication is feasible, safe and related with a good clinical outcome. This indicates 
that the use of heparin-bonded endografts might be a valid alternative for surgery in this 
specific g roup of patients. The technique, however, may also be considered as an extra 
treatment option before even considering a surgical reconstruction. In our series, failure 
of the endoluminal bypass did not lead to any major amputations or worsening of the 
clinical status , which confirms the observation of McOuade et al. , that the use of covered 
stents in SFA occlusive disease is not related to an increased amputation rate, due to 
covering collaterals, in case of failure 1 3 • 
Femoropopliteal bypass surgery is related to morbidity, including early postoperative 
complications such as wound healing problems in 5% to 44% and edema in up to 40%-
100%1 7-20• The minimal invasive character of an endovascular reconstruction may well 
decrease morbidity in these, often frail, patients. The overall complication rate of in our 
study was only 7 .5%, which then again may seem high for an endovascular procedure , 
emphasizing the vulnerability of this patient group. There were no wound healing 
disturbances and only one patient had a self-limiting postoperative edema. Comparative 
studies with either bare metal stents and surgical bypass , assessing both patency rates 
and quality of life, such as the SUPERB (SUrgical versus PERcutaneous Bypass) and the 
VIBRANT (Viabahn Versus Bare Nitinol Stent in the Treatment of Long Lesion [� 8 cm] 
Superficial Femoral Artery Occlusive Disease) trials are essential in defining the role of 
heparin-covered endografts in the treatment algorithm of chronic occlusive SFA disease21 • 
In the last decade, multiple case series and few randomized trials have been published 
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focusing on non-heparin-bonded endografts for SFA occlusive disease. Treatment 
strategies greatly varied, making comparisons inappropriate. The previous studies 
showed 1-year primary patency rate varying between 44% and 93% with large variation 
in treatment length (between 7 and 26 cm)1 0-1 2• Moreover, there were large differences 
in the post-interventional antiplatelet strategy. In most series patients were treated with 
acetylsalicylic acid while in half of them clopidogrel was added for 6 weeks to over 3 
months. A study focusing on endovascular treatment of popliteal artery aneurysms, 
showed that the use of clopidogrel was the only predictor of outcome22• In contrast to 
previous studies, patients were consequently treated with statins in our series, according 
to current guidelines on secondary risk prevention. Statins not only lower cholesterol, but 
may also reduce the incidence of restenosis by their anti-inflammatory, anti-proliferative, 
and anti-thrombogenic effects23 • 
In the study of McOuade et al. ,  5mm endografts seemed to perform worse compared 6 
and 7 mm endografts at 2-year follow-up24• In the present study, we could not confirm 
this observation using heparin-bonded endografts, although our 5mm group was very 
small. Further risk analysis did not reveal any significant predicting factor for failure. The 
use of 3 stents was associated with a, non-significant, 25% decrease in 1-year patency 
when compared to the use of 1 or 2 endografts. The numbers, however, were low and 
the lack of statistical significance may well represent a type I I  error. Multiple zones of 
overlap may decrease flexibility of the device, thereby possibly reducing performance 
and have also been associated with an increased incidence of stent fractures following 
endovascular treatment of popliteal artery aneurysms25• Fortunately, with the introduction 
of a 25 cm endograft in 2010, the use of more than 2 stents is usually no longer necessary. 
Moreover, patients with a single vessel run-off appeared to be prone for failure in our 
series. However, the low number of patients with a single vessel run-off in this study 
renders any conclusion unreliable. 
With the introduction of the heparin-bonded technology in the endograft the design of 
the stent has also been changed in order to reduce edge stenosis. The proximal edge of 
the endograft has no longer a straight, but a contoured edge, that reduces infolding in 
case of oversizing, maintaining laminar blood flow and thus preventing intimal hyperplasia. 
The results of the present study may therefore not be attributed to the heparin-bonding 
technology, only. 
Whether the use of covered stents for long chronic occlusions of the SFA is cost-effective 
I 
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may not be concluded from the present data. The use of covered stents is likely to increase 
procedural costs. Additionally, endovascular techniques are often related to a higher 
incidence of re-interventions in order to maintain patency. In our series only 4 patients 
required an additional angioplasty procedure to prevent failure. On the other hand, the 
mean hospital stay and complication rate is usually lower, due to its minimal invasive 
character. Further studies, focusing on cost-effectiveness are indicated. Prospective 
randomized trials are needed to compare the current gold standards, bare metal stents 
and venous bypass versus heparin-bonded ePTFE-covered stent grafts , which should also 
include cost-effective analyses. Moreover, comparative studies with the newly developed 
drug-eluting stents are essential before considering the use of endografts as a routine 
treatment. 
In conclusion,  the heparin-bonded endoluminal bypass is associated with acceptable 
patency rates and is related to a low morbidity and mortality rate. Furthermore,  it does 
not exclude the later placement of a venous bypass. Randomized trials are indicated, 
before considering the technique a new standard of care and to elucidate the place of the 
technique in the treatment algorithm of chronic SFA occlusive disease. 
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Abstract 
Objective 
Endografts represent a relatively new treatment modality for occlusive disease of 
the superficial femoral artery (SFA), with promising results. Endografts , however, 
may occlude collateral arteries , which may affect outcome in case of failure. The 
purpose of this study was to analyze the clin ical outcome of failed endografts in  
patients with SFA occlusive disease. 
Methods 
All patients treated with a polytetrafluorethylene (ePTFE) covered stent between 
November 2001 and December 2011 were prospectively included in a database. 
Patients with a failure of the endograft were retrospectively analyzed. Clin ical and 
hemodynamic parameters were assessed before the i n itial procedure and at the 
time of failure. Outcome of secondary procedures were analyzed. 
Results 
A total of 341 patients were treated in  the study period of which 49 (14%) failed 
durin g  follow-up. Forty-three percent of patients (n =21) presented with the same 
Rutherford category as before the in itial procedure, 37% (n=18) with an improved 
category and 20% (n =10) with a deteriorated category. The ankle brachia! index was 
sign ificantly lower at time of failure (0.66 ± 0.19 vs. 0.45±0.19, p<0.002). Seventy­
six percent of patient with a failure needed secondary surgery. The 1-year primary, 
primary-assisted and secondary patency rates of secondary bypasses were 55.1 %,  
62.3% and 77. 7%, respectively. The amputation rate was 4.1 % (n=2). 
Conclusion 
Failure of endografts is not associated with a deterioration in clin ical state and is related 
to a low amputation rate. The hypothesis that covered stents do not affect options for 
secondary reconstructions could not be confirmed as 25% of patients with a failure 
ended with a BK bypass. Secondary surgical bypasses are correlated with a poor patency. 
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I ntroduction 
Nitinol stents have improved the outcome o f  endovascular treatment of occlusive disease 
of the superficial femoral artery (SFA). Randomized trials have shown their superiority in 
lesions from 6.5 to 9.5 cm length1 •2 while in shorter lesions no differences compared to 
angioplasty only3• In more extensive lesions bare metal stents are likely to perform worse 
due to the occurrence of in stent restenosis. Therefore surgical reconstruction is still the 
gold standard for lesions over 1 5  cm in length4 • Bypass surgery, however, is associated 
with complications and a prolonged hospital admittance. 
The use of covered stents may increase the results of endovascular treatment of more 
extensive disease in the SFA. Various case series have been published with mixed 
results, most likely due to large variances in both lesion and patient characteristics. In a 
multicentre randomized trial McOuade et al. have shown that using endografts similar 
patency rates were achieved compared to above knee (AK) femoropopliteal bypasses 
after 4-years follow-up, without differences in complication rates5 • With the development 
of the heparin-bonding technology the results of endografts may further increase. In a 
recent study a 1 -year primary patency of 75%, a primary-assisted patency of 81 .7%, and 
a secondary patency 89% was described in a series of mostly Trans Atlantic lntersociety 
Consensus (TASC II) D lesions6 • 
A possible shortcoming of covered stents might be the coverage of collateral arteries. It 
is believed that this wil l  reduce limb salvage rate or may change the level of amputation 
after failure of the graft. However, in the above mentioned randomized trial failure of 
endografts did not increase the amputation rate. The aim of the present study is twofold. 
First, we aim to study the clinical state of patients that presented with a failure of covered 
stents used for SFA occlusive disease, that had possibly covered collateral arteries. Second 
we intend to assess the outcome of eventual secondary reconstructions in case of failure. 
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M ateria ls and Methods 
Al l  patients treated with a polytetrafluorethylene (ePTFE) covered endograft between 
November 2001  and December 201 1 in the Rijnstate Hospita l Arnhem, the lsa la  C l in ics 
Zwol le,  and the Antonius Hospita l Sneek, the Netherlands were prospectively gathered 
in a database. The ind ication for endovascu lar  treatment was based on anatom ica l 
su itab i l ity and the preference of both the patient and surgeon . I n  a l l  patients there was an  
i ndication for surgery and treatment with an endograft was offered as a m in ima l  invasive 
a lternative. Routine fol low-up consisted of c l in ica l  assessment, ankle-brachia !  i ndex (ABI )  
measurements and u ltrasound stud ies at 1 ,  3,  6 and  12 months and yearly thereafter. 
Compl ications and addit ional treatments were reg istered in the hospita l fi les. 
Al l patients who presented with a fa i led endograft, either c l in ica l ly or during routine 
surve i l l ance, were included i n  the study and retrospectively ana lyzed . Demographics, 
c l in ica l  status and medica l  history were noted . Procedura l  aspects of the i n itia l  procedure 
and fol low-up  data were retrieved, as was the fol low-up of a secondary procedure if 
app l icable.  Cardiovascu lar  risk factors were scored according to the Society for Vascu lar  
Surgery medica l  comorbid ity g rading system.  C l in ical symptoms at  the t ime of the 
i n itia l  procedure and symptoms at the time of fa i l u re were categorized accord ing to the 
Rutherford classification . ABI measurements at the time of fa i l u re were com pared with AB I 
measurements before insert ion of the endografts. Lesions were reviewed at the time of 
the i n itia l  procedure and at the time of fa i l u re, and scored according to the TASC II criteria  
by two authors (M L, BG)4 • The n u m ber and patency of  the run-off vessels were scored at 
both time points. Patency of run-off vessels was classified as the either open , open with 
stenosis (peak systol ic  velocity ratio >2.5) or occlus ion.  The outcome of a l l  secondary 
procedures was assessed as was the l imb  salvage rate. 
Treatment protocol 
The treatment protoco l has been previously described6• Briefly, the common femora l  
artery was approached e ither percutaneously o r  surg ica l ly. When there was a concomitant 
lesion in the common or profunda femora l  artery, an endarterectomy was performed . 
Heparin  and antibiotic profylaxis were admin istered. The d iseased segment was passed, 
either endo lumina l  or subintima l ,  using a 0.035"  Terumo® gl ide-wire (Radiofocus® 
G u idewire M, Teru mo Medica l Corporation , E lkton ,  M D, USA) and a catheter, and  a 
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subsequent a re-entry was created distally. The segment was pre-dilated and endografts 
(Viabahn Endoprosthesis, W.L. Gore & associates, Flagstaff, AZ, USA) were positioned 
from distal to proximal with minimal or no oversizing. Sizing was performed using a 
computed tomography or magnetic resonance scan. The entire diseased segment was 
covered with endografts, which were postdilated with an angioplasty balloon of the same 
size as the endograft. Control angiography of the endograft and outflow vessels was 
performed routinely. Postprocedural, patients received statin treatment and dual anti­
platelet inhibitors, unless oral anticoagulation was indicated for other reasons. 
Definitions 
Failure of the en dog raft was defined as occlusion of the endograft, with or without clinical 
symptoms, not responding to fibrinolytic or surgical therapy or not eligible for therapy. 
An occlusion was defined as the absence of flow in the treated segment of the superficial 
femoral artery. Primary patency was defined as the absence of restenosis or occlusion 
in the target vessel. Restenosis was defined as a peak systolic velocity (PSV) ratio >2.5, 
as measured on ultrasound scanning. Primary-assisted patency was defined as patency 
achieved by secondary endovascular interventions to treat restenosis of the target vessel. 
Secondary patency was defined as patency after thrombolytic or surgical treatment 
performed for bypass occlusion. Limb salvage was defined as the absence of an above 
ankle amputation. 
Endpoints 
The primary endpoints of the study were the comparison of the initial- and post-failure 
Rutherford category and the clinical outcome of failures, including amputation rate, 
and patency rates of eventual secondary interventions. Secondary endpoints were the 
differences between initial and post-failure ABI ,  differences between the quality of outflow 
vessels at the initial procedure and post-failure. 
Statistical Analysis 
Continuous variables are presented as mean or as median with range, non-parametric 
values as median and range and categorical variables as counts and percentages. 
Univariate analyses were performed to identify a possible influence of various confounding 
factors acting on the Rutherford classification at the time of failure. Kaplan-Meier survival 
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analysis was performed to asses primary patency after secondary surgical intervention. 
P-value <0.05 was considered statistically sign ificant. The data were analyzed using IBM 
SPSS Inc. statistics (version 19, 2010). 
Resu lts 
During the study period a total of 341 patients were treated with an endograft for 
occlusive SFA disease. The median follow-up was 24 months (range 0-72 months). During 
follow-up 49 patients presented with an occluded endograft. The majority of these were 
male (67 .3%) and the mean age was 66 ± 9 years. The incidence of cardiovascular risk 
factors is shown in Table 1. 
Cardiovascular Risk Factors 
Hyperl ipidemia 
Normal cholesterol 
M i ldly elevated, d ietary 
Type I I ,  I l l ,  IV, dieta ry 
Treated with drugs 
Diabetes Mel l itus 
No 
Adu lt, d ietary 
Adult, insu l i n  dependent 
Juveni le d iabetes 
Hypertension 
No 
Treated with one drug 
Treated with two drugs 
Treated with three drugs 
- - -
Renal Fai lure 
No 
--- - -
Creatin in 1 .5-3.0; GFR 30-50 
Creatin in  3.0-6.0; GFR 1 5-30 







O2-needed, pulmonary hypertensi� _ 
--
No. of patients (%) 




36 (73 .5) 
5 ( 1 0.2) 
8 (1 6.3) 
0 (0) 
1 1  (22.4) 
1 1  (22.4) 
1 0  (20.4) 
1 7  (34.7) 
-- --




42 (85 .7) 
5 (1 0.2) 
2 (4. 1 )  
0 (0) 
�- --- - -
- -
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Cardiovascular Risk Factors No. of patients (%) 
Cardiac status I 
Asymptomatic 31 (63.3) 
Non recent Ml (>6m), or asymptomatic Ml on ECG 11 (22.4) 
Stable AP, arrhytmias, treatable heart failure 7 (14.3) 
Instable AP, recent Ml (<6m) 0 (0) 
----
Carotid status 
No disease 43 (87.8) 
Asymptomatic, signs of disease 2 (4.1) 
TIA/CVA w/o rest symptoms 3 (6. 1 )  
CVA w rest symptoms 1 (2) 
Pre-operative medication 
Acenocoumarol 4 (8.2) 




Clopidogrel 1 (2) 
Dipyridamol 4 (8.2) 
Statin 37 (75.5) --
ASA 
1 2 (4.1) 
L 2 32 (65.3) 3 15 (30.6) --
Table 1 .  Incidence of cardiovascular risk factors of patients presenting with an occluded endograft. 
AP = angina pectoris; ASA = American Society of Anesthesiologists; CVA = cerebrovascular 
accident; Ml = myocardial infarction; TIA = transient ischemic attack. 
Prior to the initial procedure 3 patients (6.1 %) had already undergone balloon angioplasty 
of the SFA without stent placement, and 5 patients (10.2%) had undergone angioplasty 
of the iliac artery with (n=3) or without (n=2) bare metal stent placement. Two patients 
were treated for an abdominal aneurysm with an endograft and one had undergone an 
endarterectomy of the ipsilateral proximal SFA. 
Initial procedure 
Before the initial procedure the Rutherford category was 3 in 38 patients (77 .6%) , category 
4 in 9 patients (18.4%) , category 5 in 1 patient (2%) and category 6 in another patient 
(2%). The mean maximum walking distance for patients with disabling claudication was 
143 ± 91 meters. Before treatment, mean ABI in rest was 0.66 ± 0.19 and after exercise 
0.39 ± 0.15. Two lesions (4.1 %) were classified as TASC II A lesions, 14 (28.6%) as TASC I I  
B lesions, 14 (28.6%) as TASC II C lesions and 19 (38.7%) as TASC I I  D lesions. The mean 
lesion length of the SFA was 13.4 ± 10.0 cm and in 5 patients (10.2%) there was a flush 
I 
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occlusion of the SFA. Other lesion characteristics are shown in table 2. 
I Prior to endograft failure Post-failure P-value 
N=49 N=49 
N=47 N = 1 8 
AB/ 0 .66±0. 1 9  0.48±0. 1 6  0.002 
Rutherford Classification N=49 N=49 
1 0 3 (6. 1 %) 
2 0 1 4  (28.6%) 
3 38 (77.6%) 1 8  (36.7%) 
4 9 (1 8.4%) 7 (1 4 .3%) 
5 1 (2%) 4 8.2%) 
6 1 (2%) 3 (6 . 1 %) 0.328 
Level patent popliteal artery 
N=47 N=45 
P1 37 (75 .5%) 26 (53. 1 %) P2 
P3 
9 (1 8.4%) 8 (1 6 .3%) 
Occlusion 1 (2%) 2 (4. 1 %) 
0 9 (1 8 .4%) 0.001 
Anterior tibial artery 
N=48 N=42 Open 
3 1  (63.3%) 22 (44.9%) 
0. 1 3  
Open with stenosis 
7 (1 4.3%) 6 (1 2.2%) Occluded 
1 0  (20.4%) 1 4  (28.6%) 
Posterior tibia l artery 
N=48 N=42 Open 
37 (75.5%) 27 (55. 1 %) Open with stenosis 
5 (1 0.2%) 4 (8.2%) 
0.03 
Occluded 
6 (1 2.2%) 1 1  (22.4%) 
Peroneal a rtery 
N=47 N=42 Open 
34 (69.4%) 30 (6 1 .2%) Open with stenosis 
5 (1 0.2%) 3 (6. 1 %) 
0.57 
Occluded 
8 ( 1 6.3%) 9 ( 1 8.4%) 
Table 2. Clinical outcome prior to endograft placement versus post-failure of patients presenting with 
an occluded endograft. AB/ = ankle brachia/ index 
During the initial procedure, a concomitant endarterectomy of the common femoral artery 
was performed in three patients (6.1 %), of the external iliac artery in two patients (4.1 %), 
of the proximal SFA in one patient (2.0%) and of the deep femoral artery in another 
patient (2.0%). Angioplasty of the popliteal artery was performed in four patients (8.2%). 
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In 25 patients (51 %) only one endograft was used, while 15 patients (30.6%) were treated 
with two endografts, 6 patients (12.3%) with three endografts and in three patients (6.1 %) 
four endografts were used. In the vast majority (93.9%) a 6 mm endograft was used. 
One patient was treated with a 5 mm endograft and the remaining two patients were 
treated with a 7 mm endograft. Thirty-seven patients (75.5%) were treated with a regular 
endograft, while the remaining 12 patients were treated with a heparin-bonded endograft 
(24.5%). 
After the procedure, 30 patients (61.2%) were treated with dual anti-platelet therapy, 8 
patients (16.3%) received acetylsalicylic acid 80mg and one patient (2%) was treated with 
clopidogrel 75mg only. Six patients (12.2%) were treated by coumarin derivates because 
of other indications of which two received also acetylsalicylic acid. Of the remaining 4 
patients (8.2%) postoperative medication could not be retrieved. Seventy-four percent of 
patients (n=36) were treated with statins. After the initial procedure, a clinical improvement 
was observed in all but one patient. This patient had an early occlusion and was treated 
with chemical thrombolysis. The ABI was significantly increased to 0.95 ± 0.26 (p<0.001). 
The 30-day morbidity was 8.2% (n=4), and included wound infection (n=1), hematoma 
(n=1), decubitus (n=1) and a deep vein thrombosis (n=1). During the first year after the 
initial procedure 15 of 49 patients (30.6%) that finally failed had already an occlusion of 
the endograft, that was successfully treated by surgical thrombectomy (n=1) or chemical 
thrombolysis (n=14). Eleven patients underwent an additional angioplasty of the SFA or 
popliteal artery with (n=4) or without (n=7) additional stent placement and in 2 patients a 
toe amputation was performed. 
Outcome of failures 
The median time from initial surgery to failure was 7 .3 months (range 0.4-7 4.4 months). 
Six endografts failed within the first 30 days, 23 others within the first 6 months and 
another 7 within the first year after treatment. The remaining endografts failed at 18 
months (n=4), 28 months (n=4), 32 months (n=2), 43 months (n=2) and 74 months (n=1). 
The Rutherford categories of these patients after failure are depicted in table 2. The 
overall clinical state after en dog raft failure did not significantly differ from the clinical state 
before the initial procedure (3 .1 ±1.3 vs. 3 .3 ±0.6, respectively, p=0.33). Of the 49 patients 
21 (42.9%) presented within the same Rutherford category, 18 (36.7%) with an improved 
category and 10 (20.4%) with a deteriorated category. The maximum walking distance 
I 
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after fail ure was recorded in 22 patients (44.9%). N ineteen patients (38.8%) had a mean 
maximum walking distance of 158 ± 127 meters, which was not significantly different 
from their maximum walking distance before the initial procedure (p=0.69). Three others 
(6. 1 %) had an unlimited walking distance. Univariate analysis of cardiovascular risk factors 
did not show any significant correlation with c l inical state after failure. The mean ABI 
after failure was significantly lower than the ABI before the initial procedure (p<0.01 ). 
However, the post-fai l ure ABI was often missing. When comparing the index ABI with 
the post fai l ure ABI in the 18 patients with an known post-failure ABI the difference was 
still significant (0.64 ± 0.14 vs. 0.48 ± 0.16, respectively, p<0.01 ). At time of failure, the 
level at which the popliteal artery was patent was significantly more dista l ly, compared to 
before baseline (p<0.001). 
Twelve patients (24.5%) with a fai led endograft were treated conservatively and 37 
patients (75 .5%) underwent a secondary reconstruction . The median fol low-up of the 
conservatively treated group was 9.9 months (range 0.4-36.4 months). The maximum 
walking distance in this subgroup varied from 1000 meters to an unrestricted walking 
distance. All patients of the conservative group were discharged from further follow-up 
and were categorized as Rutherford 1. 
The median fol low-up after secondary surgery was 7 .5 months (range 0.7-100.2 months). 
In 34 patients (69.4%) a secondary bypass was constructed. In 22 of them (44.9%) an AK 
femoro-popl iteal bypass was constructed with either vein (n=9) or prosthetic material 
(n=13). Twelve patients (24.5%) were treated with a below-knee (BK) bypass with either 
vein (n= 9) or prosthetic material (n=3). At 1 year, the primary patency was 55 .1  %, the 
primary-assisted patency was 62.3% and the secondary patency was 77.7% (Fig. 1). 
Re-interventions of the secondary bypass were performed in 8 patients (36.4%) with 
an AK bypass and in 5 patients (41.7%) with a BK bypass, incl uding angioplasty (n= 
5), chemical thrombolysis (n=1) and surgical thrombectomy (n=2). In 3 patients a third 
bypass was constructed, a l l  BK. In total two of 49 patients (4. 1 %) underwent a below-knee 
amputation, one after unsuccessful chemical thrombolysis due to endograft fai lure and 
one after fai l ure of the secondary procedure. The patient with an unsuccessfu l  chemical 
thrombolysis had an infected hematoma in the lower leg, possibly due to thrombolytic 
treatment and underwent a below-knee amputation 7 days after bypass surgery. The 
other patient suffered from a wound infection of the foot after receiving an AK prosthetic 
bypass and underwent a below-knee amputation 3 months after secondary surgery. Both 
Outcome of failed endografts of SFA I 69 
patients were diabetic and presented initially with Rutherford category 3 ,  and returned 
with category 3 and 6, respectively, at time of endograft failure. Amputations were 






Limbs at risk 
Primary patency 34 20 
Primary assisted patency 34 22 
Secondary patency 34 24 
Patency {%) 
Primary patency 1 00 73.1 
Primary assisted patency 100 79.7 
Secondary patency 100 86.4 
SE (%) 
Primary patency 0 8.2 
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Figure 1 .  Kaplan-Meier curve showing primary, primary-assisted and secondary patency after secon­
dary surgery. 
I 
70 I Chapter 4 
Discussion 
The major drawback of using endografts for occlusive arterial disease is considered to be the 
potential occlusion of collateral arteries, as this may worsen clinical outcome in case of failure. 
In the present study we have shown that failure of endografts, inserted for occlusive disease of 
the SFA, does not deteriorate the clinical state of patients compared to the baseline situation. 
The data therefore do not support the hypothesis that endograft placement, possibly 
covering collateral circulation, worsens patients clinical outcome after failure. Seventy-six 
percent of patient with a failure needed secondary surgery. The theory that the use of covered 
stents does not affect the options for secondary reconstructions in case of failure could not be 
confirmed as 25% of patients with a failure ended with a BK bypass. 
Data of the present study may contribute to the discussion on the place of endografts in 
the treatment algorithm of SFA occlusive disease. It has been thought that endografts may 
postpone surgery in this category of often frail patients and may be a 'bridge to surgery'. 
In the present study we found that after a mean follow-up of 2 years no secondary surgery 
was indicated in 89% of patients due to patency of the bypass or due to the fact that 
there was no indication after failure. Almost 25% of our population had no remaining 
symptoms after occlusion of the endograft. The observation that 80% of patients do not 
show deteriorated clinical outcome after failure and may even improve suggests that 
the covering of collaterals may not be clinically relevant in this group of patients. This , 
however, may not be extrapolated to the popliteal artery, which is regularly involved in 
TASC I I  D lesions. It seems reasonable to assume that the preservation of collaterals in this 
area may contribute to the clinical outcome after failure. The use of re-entry devices or the 
combined antegrade-retrograde approach may contribute to spare as much collaterals as 
possible at the popliteal level7 • 
Surprisingly, although endograft thrombosis was related to a decreased ABI ,  the clinical 
state was often similar or even improved when compared to the baseline situation. The 
reason for this is unknown, but it may be hypotized that a similar phenomenon occurs as 
is described during walking exercise training,  where an increased clinical performance is 
not related to an increased ABl8 .This emphasizes the discrepancy between clinical state 
and the ABI that might occur, due to unknown reasons. Possibly the treatment of the 
occlusion with an endograft, allowing a rapid return to daily activities , had provided the 
patient sufficient time to develop new collaterals. 
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In the present study 33% of patients showed a progression of disease in the popliteal 
artery distally from the bypass after failure. This was reflected by a decreased AB I ,  while 
the quality and quantity of crural outflow vessels was not affected, except for the posterior 
tibial artery. A condition, that may be considered as ongoing disease. Obviously, this 
may have contributed to the occurrence of failure. Due to this progression a BK bypass 
was indicated in 1 out of 3 patients, possibly affecting the outcome of the secondary 
procedure. In half of them prosthetic material was used, mostly because the saphenous 
vein was unsuitable. This is in line with the observation of Gisbertz et al. that only 45% 
of patients have a suitable saphenous vein available, as was shown in a randomized trial 
comparing surgery to remote endarterectomy9. The outcome of secondary surgery was 
rather disappointing in the present study. Although it was a mixed group of AK and 
BK bypasses, the primary 1 -year patency was as low as 55.1 %. Nolan et al. recently 
came to the same conclusion in a retrospective analysis of 1880 lower limb bypasses 1 0 • 
They found that prior ipsilateral endovascular revascularization or bypass surgery, but 
also dialysis dependence, the use of a prosthetic conduit, and distal bypass target were 
independent predictors of higher 1-year amputation and graft occlusion rates. The high 
failure rate of secondary procedures might be at dispense of progression of disease and 
the vulnerability of this specific patient group or due to other risk factors, such as co­
morbidity, a poor run-off and type of graft material. In the present cohort no composite 
or arm vein conduits were used. The sample size of our cohort withheld us from further 
analysis and conclusions on this point. 
Regardless of the fact that secondary surgery is related to a relatively high failure rate 
the amputation rate was low in our study. The amputation rate was 4% in the group 
of patients with a failed bypass, but only after failure of a secondary procedure. The 
amputation rate after failure of the secondary procedure was only 4%, which is much 
lower than the 31 %, as described by Nolan et al. Our data in line with previous reports 
on the outcome of endografts for occlusive SFA disease which also described low overall 
amputation rates (0-4%)5• 1 1 ·12 • Defining the role of endografts for occlusive SFA disease 
remains a future challenge since it depends on many variables, including the outcome of 
failures described here. Besides patency rates, issues like quality of life and cost benefit 
analysis are also important in the discussion. Hopefully, randomized trials, such as the 
SUrgical versus PERcutaneous Bypass (SUPERB) trial will provide answers to settle this 
debate 1 3• 
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Limitations of the present study are mainly related to the retrospective analysis of the 
prospective database. Data were not always complete which may have affected outcome. 
Moreover, although this is the largest group of failed endografts described to date, the 
sample size is sti l l  relatively small. This renders a sub-analysis to various factors affecting 
the outcome of failure unreliable. Additional comparative studies are indicated to confirm 
our data. During the study period the design of the endograft has been changed as 
the heparin-bonding technology and the contoured edge were introduced. The present 
study design unfortunately does not allow a comparison between both endografts , since 
sample sizes are too low. 
In conclusion , we have shown that failure endografts is not related to a deterioration of 
the clinical state in the majority of patients , thereby rejecting the hypothesis that coverage 
of collateral arteries reduces the limb salvage rate after surgery. Secondary procedures 
are related to low patency rates, but amputation rates are low. 
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Abstract 
Background 
The use of endografts for superficial femoral artery (SFA) occlusive disease is matter 
for debate and the optimal treatment for thrombosed endografts has not been 
clearly  elucidated. The aim was to evaluate the efficacy and outcome of thrombolysis 
and thrombectomy of thrombosed endografts inserted for SFA occlusive disease. 
Methods 
Patients treated with a polytetrafluoroethylene endograft between November 
2001 and December 2011 were gathered in a database and those that underwent 
thrombolysis or thrombectomy were retrospectively analyzed. 
Results 
Seventy-nine patients presented with an endograft thrombosis of which 46 (58%) 
were treated with thrombolysis (n=40 , 87%) or thrombectomy (n= 6,  13%). The 
clinical state was classified as category I in 15 (33%), Ila in 20 (43%) and l ib in 11 
patients (24%). Median time from insertion to thrombosis was 3 months (range 0-53 
months). Thrombolysis was successful in 38 patients (95%) and the time needed for 
lysis was 24 hours (range 3-48 hours). Thrombectomy was successful in al l  6 patients. 
Thrombosis without causal lesion occurred more in occlusions that presented <30 
days after insertion (p=0.01 ). The primary, primary-assisted, and secondary patency 
rates of thrombolysis and thrombectomy at 6 months were 56% and 67%, 56% and 
67% and 68% and 67%, respectively. Three patients eventually required a major 
amputation. 
Conclusion 
Thrombolysis and thrombectomy of thrombosed endografts in the SFA is effective 
and safe. Patency rates after treatment are moderate but in two thirds of the patients 
a prolonged secondary patency can be achieved. 
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I ntroduction 
The role of  endografts in the  treatment a lgorithm of  superficia l femora l  a rtery (SFA) 
occlusive d isease is sti l l  under debate. According to the TASC I I  gu idel ines 1 , su rgica l  
reconstruction is the gold standard for lesions longer than 1 5  cm in length . Su rgery, 
however, is associated with more compl ications and a prolonged hospita l stay2 • A 
random ized tria l  has shown that with the use of endografts sim i l a r  patency rates may be 
ach ieved as with an above the knee femoropoplitea l  bypasses up to 4-years fol l ow-u p3 • 
With the introduction of the heparin-bonding technology the resu lts of endografts may 
further increase. Recently, we have described a 1 -year primary patency of 76%, a primary­
assisted patency of 82%, and a secondary patency of 89% in a series of long occlus ive 
lesions of the SFA treated with such endografts4 • 
Acute thrombosis often caused by edge stensosis is the most common cause of fa i l u re 
of an endograft, and may lead to l imb-threatening conditions. Thrombectomy is an  
effective treatment moda l ity o f  acute th rombosed native arteries and  bypass grafts, 
but thrombolysis has developed into an accepted treatment a lternative. In  a Coch rane  
review i t  was shown that to  date none  of these two moda l ities can  be advocated as in itia l  
treatment a s  there was no overa l l  d ifference in l imb salvage or death a t  one  yea r between 
surgery and th rombolysis5 • In  another recent review it  was concluded that catheter­
d i rected thrombolysis should be considered a complementary and not a competing 
technology with surg ical revascu larization, with an acceptable low compl ication rate6 • 
To date, no studies have been performed focusing on the optima l  treatment moda l ity of 
thrombosed endografts, inserted in the SFA for occlusive disease . The a im of the present 
study was to eva luate the efficacy and outcome of thrombolysis and th rombectomy of 
thrombosed endografts that were inserted for SFA occlusive d isease. 
Materia ls  and M ethods 
Al l patients, treated with a polytetrafluoroethylene (ePTFE) covered endograft in three 
hospita ls (Rijnstate Hospita l Arnhem, lsa l a  C l in ics Zwol le ,  and Antonius Hospita l Sneek, 
The Netherlands) between November 2001 and December 201 1 were prospectively 
gathered in a database and retrospectively ana lyzed. Anatomica l  su itabi l ity and preference 
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of both patient and surgeon were considered before opting  for endovascu lar  treatment. 
C l in ica l assessment, an kle-brach ia !  index (ABI) measu rements and u ltrasound scans at 1 ,  
3, 6 and 1 2  months and yearly thereafter, were aspects of routine  fol low-up,  inc lud ing the 
registration of compl ications and  additiona l  treatments in the hospita l fi les. Th is database 
was previously used for the ana lysis of another cohort, focusing on the c l i n ica l  outcome 
of patients that presented with a defin itive fa i l u re of the endograft7 • I ncl usion criteria for 
the current study were patients that presented with an thrombosed endograft, either 
during admission or during routine survei l lance, and were treated with thrombolysis or 
thrombectomy. The choice was mostly based on the c l in ica l state of the patient. I n  case of 
acute ischemia with muscle wea kness and sensory loss su rgery was ind icated. 
Patient demograph ics, c l i n ical status, medica l h istory were retrospectively ana lyzed . 
Additiona l ly, the procedu ra l  aspects of the endograft imp lantation and th rom bolysis or 
throm bectomy, as wel l  as the fo l low-up  after the secondary procedure were gathered. 
Co-morbid ity was scored according to the Society for Vascu la r  Surgery (SVS) and 
American Association for Vascu lar  Surgery (AAVS) medica l co-morbidity scoring  system8 • 
C l in ical symptoms and ABI  measurements at the time of the imp lantation and at the 
time of occl usion were gathered . The Rutherford classification was used to categorize 
the c l in ical symptoms. Characteristics of the lesions were reviewed at the time of the 
index procedu re and scored according to the TASC I I  criteria 1 and scored additiona l ly 
at the time of occlusion .  Patency of run-off vesse ls was scored at both t ime points. The 
amputation rate and the outcome of secondary procedures were assessed . 
Endograft placement 
The treatment protocol of endograft placement has been previously described4 . Briefly, 
the common femora l  a rtery was a pproached e ither percutaneous or surg ica l ly. The 
diseased segment was passed using a Terumo® wire (Teru mo Medical  Corporation,  
E lkton , M D, USA) and a catheter. Subsequently a re-entry was created dista l from the 
lesion , the segment was pre-di lated and endografts (Viabahn Endoprosthesis, W. L. Gore 
& associates, Flagstaff, AZ, USA) were positioned from d ista l to proxima l  with min ima l  
oversizing .  The enti re d iseased segment was covered with endografts, which were post­
di lated with an angioplasty ba l loon of the same size as the en dog raft. Contro l  ang iography 
of the bypass and outflow vessels was performed routine ly. 
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Thrombolysis 
Patients underwent a retrograde puncture of the common femora l  a rtery under loca l 
anesthesia using the Seldinger technique. Through a 6Fr sheath a thrombolys is catheter 
(Un i-Fuse™ , Ang iodynamics, Latham, NY) was inserted into the thrombosed endograft. 
Then, a bo lus of 1 00.000U medicinase (Abbokinase®, Abbott Laboratories, Ch icago, 
I L) was infused into the thrombus, fol lowed by a continuous infusion of 250.000U/24 
h medicinase unti l complete lysis was ach ieved. During treatment patients received 
25.000U/24h heparin ,  contro l led with repeated APTT measurements, and adapted 
if necessary. Fol low-up ang iograms were repetitively made in order to eva l uate the 
progression of thrombolysis. Any detected cause of the th rombosis was treated 
immediately, according to the loca l protocols. 
Thrombectomy 
Surg ica l thrombectomy was performed under e ither  reg iona l or genera l  anesthesia, by 
exposu re of either the common femora l  a rtery or the popl itea l a rtery. After admin istration 
of S000U of heparin, an arteriotomy was performed and bal loon catheters (LeMaitre 
Vascu la r, Bur l i ngton , MA) were used to extract the clot from the occluded endograft. Th is 
was repeated unti l  no more thrombus was extracted. The d istal and proxima l  segment 
were then flushed with heparin sa l ine and the a rteriotomy was closed using a Pro lene ™ 
6.0 (Eticon, Norderstedt, Germany) .  Imaging of the endograft was a lways performed per­
or post-procedu ra l  and any detected cause of the thrombosis was treated according to 
the local protocols. 
Definitions 
A thrombosis was defined as absence of flow in the endograft. Successfu l lysis was 
defined as clot lysis exceeding 95% of the endograft as determined by dig ita l substraction 
ang iography Primary patency after thrombolytic treatment was defined as the absence 
of treatment for restenosis or occlusion in a patent endograft after primary th rombolytic 
therapy. Restenosis was defined as a lesion with a peak systo l ic velocity (PSV) ratio >2.5, 
as measured on u ltrasound scann ing .  Primary-assisted patency was defined as patency 
ach ieved by secondary endovascu lar  intervention(s) to treat restenosis of the endograft 
after primary th rombolytic therapy. Secondary patency was defined as the a bsence of 
secondary thrombolytic or surgical treatment performed for endograft occl usion in a 
I 
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patent endograft after primary th rombolytic therapy. A defin itive fa i l u re was defined as 
occl us ion of the endograft, with or without cl i n ica l symptoms, not responding to therapy 
or not treated due to the absence of c l in ica l symptoms. Major amputation was defined as 
a n  a m putation above the ankle .  
Endpoints 
The primary endpoints of the study were the efficacy of th rombolytic treatment for 
endograft occl usion and the patency rates after treatment. Secondary endpoints included 
compl ications, secondary interventions and a mputation rate. 
Statistical Analysis 
Categorical  variables a re presented as counts and  percentages; contin uous variables 
a re presented as mean ± standard deviation or as median with range (depending on 
Gaussian d istribution) . Al l ana lyses were perform ed with SPSS 1 8 .0  (SPSS I nc . ,  Ch icago, 
I L, USA) . Kaplan-Meier surviva l ana lysis and the log-rank test were perfo rmed to assess 
primary, primary assisted and secondary patency rates after thrombolytic therapy. A two­
sided P-va lue <0.05 was considered statistica l ly s ign ificant. 
Results 
Du ring the study period a tota l of 341 patients were treated with endografts for SFA 
occlus ive d isease. A total of 79 patients had a n  occl usion of the endograft of wh ich 46 
patients (58%) were treated with either thrombolysis (n =40, 87%) or th rombectomy (n =6, 
1 3%). The median age of this g roup was 66 .8  years (range 30-80) and 33 patients (72%) 
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Patient Characteristics 
Tobacco use 
Never, > 10 years ago 






Mildly elevated, dietary 
Type 1 1, 1 1 1, IV, dietary 























�r�ated with one drug 
_J����
) 
Treated with two drugs 2 (26) 
Treated with three drugs 3 (28) 
---- -------------- -------I 
Renal Failu re 
No 
Creatinin 1.5-3.0 mg/di ; GFS 30-50 ml/min 
Creatinin 3.0-6.0 mg/di ; GFS 15-30 ml/min 





O2-needed, pulmonary hypertension 
Cardiac status 
Asymptomatic 
Non recent Ml (>6m}, or asymptomatic Ml on ECG 
Stable AP, a rrhythmias, treatable heart failure 
Instable AP, recent Ml (<6m) 
Carotid status 
No disease 
Asymptomatic, signs of disease 
T IA/stroke without rest symptoms 











I 5 (11) 
I 1 (2) 
34 (74:--7 
1 (2) : I 10 (22) 
1 (2) 
Table 1 .  The incidence of cardiovascular risk factors of patients presenting with a thrombosed endo­
graft treated with thrombolysis or thrombectomy. 
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The indication for insertion of the endograft(s) was Rutherford category 3 in 34 patients 
(74%), category 4 in 6 patients (13%), category 5 in 5 patients (11%) and category 6 in one 
patient. The mean ABI before endograft insertion was 0.65 ± 0.17, and after exercise 0.39 
± 0.15. Lesions were categorized as TASC II A in 2 patients (4%), as TASC II B in 8 patients 
(17%), TASC II C in 12 patients (26%) and TASC II D in 23 patients (50%). The mean treated 
lesion length was 17 .2 ± 10.9 cm. Other lesion characteristics are depicted in Table 2. 
Length diseased segm ent (cm) 1 7 .2 ± 1 0.9  
Diameter proxima l  SFA (mm) 4 .5 ± 1 .2 
Flush occlusion SFA 1 1  (23 .4%) 
Diameter popl itea l artery (mm) 3 .9  ± 1 .2 
Level patent popl itea l a rtery 
P1  32 (68 . 1 %) 
P2 1 3  (27 .7%) 
P3 0 
Outflow crural vessels 
Posterior tib ia l  artery open; open with stenosis; occluded 31 (66%); 5 (1 0 .6%); 8 (1 7%) 
Anterior tibi a l  a rtery open; open with stenosis; occluded 27 (57 .4%); 5 (1 0.6%); 1 2  (25.5%) 
Peroneal a rtery open; open with stenosis; occluded 35 (7 4.5%); 5 (1 0.6%); 4 (8.5%) 
Table 2. The lesion characteristics of patients presenting with a thrombosed endograft treated with 
thrombolysis or thrombectomy, prior to the endograft implantation. 
In 17 patients (37%) one endograft was used, in 15 patients (32%) two endografts, in 9 
patients (20%) three endografts, and in the remaining 5 patients (11 %) four endografts. 
The majority of patients (85%) were treated with a 6 mm endograft. The remaining 
patients were treated with either a 5 mm endograft (n= 2) or with a 7 mm endograft 
(n=S). Twenty-one patients (46%) were treated with a regular endograft and 25 patients 
(54%) were treated with a heparin-bonded endograft, based on the timeframe of their  
treatment. A concomitant endarterectomy of the common femoral artery was performed 
in 4 patients (9%). 
Endograft thrombosis 
The median time from insertion to primary thrombosis was 3 months with a range of 0-53 
months. The vast majority (89%) of thrombosis occurred within the first year after insertion 
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of the endograft(s) of wh ich 1 7  with in the first 30 days (37%). At the time of thrombosis the 
cl in ica l state was classified as category I in 1 5  patients (33%), category I la in 20 patients 
(43%) and category 1 1 6  in 1 1  patients, according to the Rutherford classification for acute 
l imb ischemia7 • The mean ABI at the time of occl usion was 0.54 ± 0.23. The median time 
from c l in ical symptoms unti l  thrombolytic therapy and thrombectomy was O days (range 
0-6 days) and O days (range 0-1 5  days), respectively. Comparing the d ifference in risk 
factors between patients undergoing thrombolytic therapy versus th rombectomy showed 
nearly the same percentages in smoking, hypertension, diabetes, cardiac status, carotic 
status, hyperl ipidemia and pu lmonary state. Comparison of the c l in ica l state between the 
two groups showed 67 % patients of the th rombectomy group had an Acute Rutherford I 
category and 33% an  Acute Rutherford 1 1 6 . In the th rombolytic group 28 % had an Acute 
Rutherford category I, 48% category I l a  and 23% a category 1 16 .  
Thrombolysis 
Complete lysis was achieved in 38 of 40 patients (95%). The median time taken for lysis 
was 24 hours, with a range of 3-48 hours. In 2 patients additional mechan ical thrombolysis 
was performed using a Hydrolyser™ (Cordis®, Waterloo, Belg i um). 
After lysis, a s ignificant l esion was found of the proximal edge in 1 6  patients, and 
was treated by ang ioplasty (n= 1 3), ang ioplasty with stenting (n=2) or extension of the 
endograft with an additional endograft (n= 1 ) .  A foca l edge stenosis of the dista l part of 
the endograft was found in 1 2  patients. They were treated with angioplasty (n = 1 0) and/ 
or extension of the endograft with an add itiona l  endograft (n=2). Other  causa l lesions 
inc luded in stent stenosis (n=2) which were both treated with angioplasty. 
No causa l stenosis of the endograft or the in- or outflow vessels  was found in 9 patients 
(22%) . Overa l l ,  in the group that presented <30 days after insertion of the endograft 
sign ificantly more patients had no causal stenosis compared with patients that presented 
at a l ater stage (47% vs. 1 4%, respectively, p=0.01 ). One patient d ied before any causal 
lesion cou ld be identified. 
Twenty-three patients (58%) had an outflow with 3 vessels after thrombolysis, 1 0  patients 
(30%) had a 2 vessel outflow, 5 patients ( 1 3%) had an one vesse l  outflow and one patient 
(3%) had no outflow vessels .  The one patient with no outflow vessels had an unsuccessfu l 
thrombo lysis and developed an  infected hematoma in the calf a nd eventua l ly required an 
above the knee amputation . 
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Complications occurred in 7 patients (18%) and included two conservatively treated groin 
hematomas, one pneumonia, one wound infection at the puncture site and two patients 
had a temporary paresis of the peroneal nerve as part of a reperfusion syndrome. No 
compartment syndromes were identified. One patient died during thrombolytic therapy 
due to an unknown cause. Unfortunately, no autopsy was performed to determine if 
cause of death was related to the thrombolysis. The median length of stay in the medium 
care unit was 1 day (range 0-2 days) and the median length of hospital stay was 5 days 
(range 2-1 9  days). 
Post-procedurally, 30 patients were treated with acetylsalicylic acid 80 mg, in 4 patients (10%) 
combined with dipyridamol 75 mg, in 16 others (40%) combined with clopidogrel 75 mg and 
in 6 patients (15%) combined with warfarin derivates. Six patients (15%) were treated with 
the combination of clopidogrel 75 mg and warfarin derivates, and three (8%) patients were 
treated with warfarin derivates only. Thirty-eight patients (95%) were on statin treatment. 
Thrombectomy 
The median duration of thrombectomy was 90 minutes (range 55-136 minutes) and 
the procedure was successful in all patients (100%). In one patient (17%) an additional 
angioplasty of the anterior tibial artery, and in 2 patients (33%) a concomitant 
endarterectomy of the common femoral artery was performed. No causal stenosis of 
the endograft was found in 2 of 6 patients (33%). Complications occurred in 3 patients 
and included conservatively treated groin hematoma (n=2) and one re-bleeding requiring 
surgery. After thrombectomy, three patients (50%) had a 3 vessel outflow, 1 patient (1 7%) 
had an outflow with 2 vessels and 2 patients (33%) had an outflow with one vessel. The 
median length of stay of the thrombectomy group was 7 days (range 4-18 days). 
Postoperatively, 4 patients received acetylsalicylic acid 80 mg; in 2 patients (33%) 
combined with persantin 75 mg and in 1 patient (17%) combined with clopidogrel 75 mg. 
One patient (17%) was treated with the combination of warfarin derivates and clopidogrel 
75 mg and one patient (17%) was treated with warfarin derivates only. All 6 patients were 
on statin treatment. 
Follow-up after primary thrombolysis or thrombectomy 
The median follow-up period after thrombolysis or thrombectomy was 14 months (range 
1-69 months). The median ABI after thrombolytic treatment was 0. 96 (range 0.28-1.18). 
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Al l patients, except one, showed cl in ica l improvement during the first month . Twenty-five 
patients (56%) were categorized as Rutherford 1 ,  8 patients (1 8%) as Rutherford 2, 2 patients 
(4%) as Rutherford 3, 2 patients (4%) as Rutherford 4, 3 patients (7%) as Rutherford 5 and 
one patient (2%) as Rutherford 6. The one patient who showed no clinical improvement 
had an unsuccessfu l primary thrombolysis and developed an infected hematoma in the 
ca lf, as mentioned above. The comparison in Rutherford category of different moments 
is shown in figure 1 .  Comparing the clinical state in Rutherford post endograft versus 
post thrombolysis 38% had the same Rutherford, 41 had a improved category and 1 9% 
had a detoriated category. Of 8 patients either the post endograft Rutherford category 
or the post thrombolysis Rutherford category was m issing .The c l in ica l state comparison 
in Rutherford of post endograft versus post thrombectomy showed 60% with the same 
Rutherford category, 20% with an improved category and 20% with a detoriated category. 
Of one patient the post endograft Rutherford data was m issing. The median Rutherford 
category pre-endograft insertion, post-endograft insertion, at occlusion and after 
thrombolytic therapy was 3 (range 1 -6), 1 (range 1 -6), 4 (range 2-6) and 1 (range 1 -6), 
respectively. 
The overa l l  primary, primary assisted and secondary patency rates after primary 
thrombolytic therapy are shown in figure 1 .  The primary, primary-assisted, and secondary 
patency rates of thrombolysis at 6 months were 56%, 56% and 68%, respectively and 
those of thrombectomy 67%, 67% and 67%, respectively. 
During the fol low-up period re-interventions were performed in 1 2  patients (26%) and 
included pla in ba l loon angioplasty (n= 1 0) of the SFA (n=4), the proximal  edge (n=3), the 
dista l edge (n=2) and the popl itea l artery (n= 1 ) . An ang ioplasty with stent p lacement 
was performed in two patients in the SFA and popl itea l  a rtery, respectively. Due to a re­
occ lusion, secondary thrombolysis was performed in 1 0  patients and thrombectomy in 
4 patients. Al l re-interventions were performed within the first 1 8  months after the fi rst 
thrombolytic treatment. 






Limbs at risk 
Primary patency 45 23 
Primary assisted patency 45 23 
Secondary patency 45 26 
Patency (%) 
Primary patency 100 60.0 
Primary assisted patency 100 59.8 
Secondary patency 100 67.2 
SE (%) 
Primary patency 0 7.6 
Primary assisted patency 0 7.6 
Secondary patency 0 7.2 
1 
1 2  1 8  
Time (months) 
1 6  12  
1 6  12 
1 8  14 
48.8 41 .8 
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Figure 1 .  Primary, primary-assisted and secondary patency rates after thrombolytic treatment of a 
thrombosed endograft, inserted in the superficial femoral artery for occlusive disease. 
During fo l low-up, a defin itive fa i l u re occu rred in 1 6  patients (36%), of which 2 were 
in itia l ly treated by th rombectomy (1 3%). In tota l ,  4 patients (25%) with a defin itive fa i l u re 
were treated conservatively, because they had no or only minor c l i n ica l  symptoms. The 
rema in ing 1 2  patients were treated with bypass su rgery. In  4 patients an above the knee 
femoropopl itea l  bypass was created, 2 with a venous conduit and 2 with prosthetic 
materia l .  The remain ing 8 patients were treated with a below the knee femoropopl itea l 
bypass, 5 with a venous conduit and 3 with prosthetic materia l ,  a l l  due to the absence of 
suitable vein .  
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During fol low-up, three of the 45 patients that were treated with thrombolysis or  
th rombectomy eventua l ly underwent a major amputation (7%) . The first patient has been 
mentioned above, a second patient, that was treated with thrombectomy, developed 
acute l imb ischemia 3 months after secondary thrombolysis and in the th i rd patient a 
fa i l u re of the above the knee prosthetic bypass occu rred. He was treated with a below 
the knee bypass and subsequently developed a progressive infection of the foot. Two 
patients presented in iti a l ly with Rutherford 3 and one patient with Rutherford 4. The 
amputations were performed 1 ,  9 and 39 months after primary thrombosis, respectively. 
Discussion 
In the present study we have shown that thrombolysis and th rombectomy are both safe 
treatment modal ities for the treatment of thrombosed endografts inserted in the SFA for 
occlusive disease. Technica l  success rates are h igh and major compl ication and amputation 
rates a re low. Patency rates after successful treatment of thrombosed endografts seem to 
be lower than those described after in itia l  placement4•9 • However, the patency rates a re 
with in range of patency rates after thrombolysis described in l iterature that vary between 
38 and 90%6 • Yet, in two th i rds of our patients prolonged secondary patency cou ld  be 
achieved and bypass surgery excluded, or at least postponed. 
In our study, 53% of patients required an additional treatment afterthrombolysis consisting 
of a PTA with or without add itiona l  stenting or stentgrafting.  I n  60% of cases an edge 
stenosis was the underlying cause of occlusion, emphasizing the urge for strict fol low-up 
and early treatment of edge stenosis. Most of the edge stenosis were treated with p la in 
ba l loon angioplasty. With in the paradigm of covering the entire diseased segment an 
extension of the endograft appears to be the most appropriate choice. Neverthe less, in 
proximity of col laterals pla in ba l loon angioplasty may be a va l id option ,  whi le the effects 
of drug e luting ba l loons remain to be stud ied. Further studies shou ld focus on the optimal  
treatment modal ity of edge stenosis. 
Overa l l ,  no causa l  lesion cou ld be identified in 24% of patients and th is was s ignificantly 
more the case in patients that presented with an occlusion <30 days after insertion of the 
endograft(s). I n  those patients no causa l lesion cou ld be identified in ha lf of the cases. 
Ana lysis of possible risk factors offa i l u re did not show any sign ificant association, especia l ly 
I 
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not in the used anticoagulation or the occurrence complications. Several studies found 
confounding factors which influence the success rate of thrombolysis, such as diabetes, a 
history of lower limb ischemia, an occluded bypass graft and poor runoff1 0-13 • Obviously 
the groups, as described in the present analysis, may wel l  have been too small to identify 
such a relation. Moreover, an occlusion without an anatomical cause may also be caused 
by prolonged flexion of the knee during sleep or activities. This appeared to be the case 
in some of our patients, but these associations are difficult to prove. Sizing is likely to be 
amongst the most important factors that could influence the incidence of edge stenosis 
and subsequent thrombosis. Additional studies on this subject are warranted. 
In our study, the vast majority of patients were treated with thrombolysis. We could not 
identify a difference in outcome between patients treated with thrombolysis and those 
with thrombectomy, but obviously the group of patients treated with thrombectomy 
is too small to draw any conclusions. After successful thrombolysis a completion 
angiogram allows a distinct determination of the vascular tree and possible underlying 
causes of endograft failure. Additionally, it has been reported that thrombolysis results 
in more patent outflow vessels compared with thrombectomy 1 4. Therefore endovascular 
thrombolysis could be the preferred treatment modality, especially in the often frail group 
of patients, with multiple comorbidities15· 1 6. 
Importantly, the clinical state of the patients who needed secondary thrombolytic therapy 
did not worsen in comparison with the primary thrombolysis. In 64% of patients the 
Rutherford categorization was equal to primary occlusion while the remaining 2 patients 
had a even better clinical state compared to primary occlusion. Although the overall 
complication rate of our series seems high (22%), most of them were minor and self­
limiting. In contrast to other studies where they reported major hemorrhagic complication 
rates varying from 4-13%1 1 • 1 7 • 1 8  our major hemorrhagic rate was low. Only 1 patient (2%) 
encountered significant bleeding which required surgery. Whether the death of one 
patient during thrombolysis was caused by bleeding cannot be concluded, as no post­
mortal study was performed. These observations support the hypothesis that thrombolytic 
therapy can always be considered, as secondary failure does not worsen clinical status of 
the patient. 
Various studies have reported amputation rates after thrombolysis of 18-25%1 6• 1 9• In our 
study, the amputation rate was only 7%. Two amputations occurred after failure of the 
secondary procedure, one after secondary thrombolysis and one after secondary bypass. 
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The low amputation rates might be partially explained by the relatively low percentage 
of patients primarily treated for critical ischemia. Still, the low amputation rates after 
endografting of the SFA are supported by other studies7 •9•20• These data provide 
circumstantial evidence that the overstenting of collaterals in the SFA does not inevitably 
lead to an endangered limb in case of occlusion. 
Limitations of the present study are mainly related to the retrospective design of the data. 
Furthermore the sample size of our cohort withheld us of further subanalysis. Therefore 
additional comparative studies are indicated to confirm our data. Discrepancies were 
seen between the hospital centers in the post-thrombolytic anticoagulation strategy. To 
date, clear evidence-based guidelines on the anticoagulant therapy after thrombolytic 
treatment are lacking and therefore future research on this topic is necessary21 ·22 • 
In conclusion our study has shown that an occlusion of an endograft, inserted in the 
SFA for occlusive disease, may be well treated with thrombolytic therapy with a low 
rate of major hemorrhagic events and low amputation rates. Patency rates seem to be 
lower compared to those after insertion, but are in line with those as described after 
thrombolysis of surgical bypasses. 
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Abstract 
Aim of study 
Redo femoropopliteal bypass surgery is associated with increased morbidity, while 
results of secondary procedures are related to a poor outcome. An endovascular 
strategy, using endografts, might provide a minimal invasive alternative avoiding 
the dissection of a previously operated groin. 
Materials and Methods 
All patients treated with a polytetrafluoroethylene (ePTFE) covered stent for 
superficial femoral artery occlusive disease between February 2009 and September 
2011 were prospectively gathered in a database. Demographics , clinical status, 
medical history, procedural aspects and follow-up data were retrieved. 
Results 
A total of 74 patients were included in the database of which five (7%) had been 
treated with a surgical femoropopliteal bypass before. The indication for intervention 
was Rutherford category three in all patients and the median ankle-brachia! index 
(ABI) was 0.68.The lesions were classified as TASC II C (n=1) and D (n=4). Technical 
success was achieved in 100% of cases and the postoperative course was uneventful 
in all patients. The median ABI had increased to 0.95. After a median follow-up 
period of 18 months, 4 out of 5 endografts remained patent. Due to a good clinical 
condition the patient with a failed endoluminal bypass was not re-operated. 
Conclusion 
The creation of an endoluminal bypass using endografts after failed femoropopliteal 
bypass surgery is feasible and safe and could be used to avoid or minimize the 
difficult and hazardous dissection of a previously operated area. 
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Introduction 
According to the Inter-Society Consensus for the management of peripheral arterial 
disease (TASC I I) ,  open bypass surgery is considered the gold standard for long occlusive 
lesions in the superficial femoral artery (SFA)1 . A review of the literature has shown that the 
primary patency rate of venous femoropopliteal bypasses is 81 % at two years and 69% 
at five years, respectively, while results of prosthetic bypasses are inferior2•3 . At five years, 
7-20% of venous bypasses and 17-40% of the PTFE bypasses have definitively failed4·5 • 
Results of thrombectomy and thrombolysis aimed to salvage these bypasses are poor. 
In a series of salvage procedures, including surgical thrombectomy and thrombolysis, 
Pedersen et al reported a primary patency rate of redo procedures of 32% at three months, 
28% at six months and 12% at 12 months6• Secondary femoropopliteal bypass surgery is 
associated with increased morbidity, including wound infection , lymphatic obstruction , 
lymphorrhea, and neurovascular injury. In a recent study, te Slaa et al. have shown that 
redo peripheral bypass operations result in significantly more postoperative edema than 
a first-time performed operation7 • 
In order to both improve long-term patency rates of secondary procedures and avoid 
the dissection of a previously operated groin , thereby possibly reducing the incidence of 
complications ,  alternative strategies may be indicated. An endovascular approach using 
endograft(s) provides a minimally invasive alternative. In a recent publication ,  McOuade 
et al. have shown that a primary endoluminal bypass, using ePTFE-covered stents , has 
patency rates comparable with above knee prosthetic grafts at 4-years follow-up8 • In 
secondary open bypass surgery prosthetic grafts are often used because the saphenous 
vein frequently has been used during the first procedure. The use of endografts for the 
creation of an endoluminal bypass as a secondary procedure has not been described 
to date. In this paper we describe the feasibility of an endovascular approach using 
endograft(s) after failed above knee femoropopliteal bypass surgery. 
Materials and Methods 
All patients with peripheral arterial disease and treated with a polytetrafluoroethylene 
(ePTFE) covered stent between February 2009 and September 2011 were prospectively 
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gathered in a database. In a l l  patients seconda ry risk prevention was performed according 
to the nationa l  g u ide l ines and a l l  patients with i ntermittent claudication were in itia l ly 
treated with (supervised) wa lking exercise. On ly those with unsuccessfu l exercise tra in ing 
were ind icated for intervention .  The ind ication for endovascu lar treatment was based on 
anatomica l  su itab i l ity and the preference of both patient and surgeon. Genera l ly, covered 
stents were used in lesions with a length of more than  1 5  cm, whi le bare meta l stents were 
used in shorter lesions. Anatomica l suitabi l ity consisted of an adequate inflow without a 
flow- l imit ing stenosis in the aorto- i l iac arteries, a patent popl iteal a rtery above the P3 
level with a diameter of at least 4.2 mm and at least one patent crura l vesse l .  
Demograph ics, c l in ica l status and medica l  h istory were noted . Procedura l  aspects and 
fo l low-up data were retrieved. Lesions were reviewed and scored according to the TASC 
II criteria 1 • Addit iona l ly lesion length , l umina l  vesse l diameters, and the number of patent 
run-off vessels were scored . 
Fol low-up consisted of cl in ica l assessment and dup lex u ltrasound scans at 1 ,  3 ,  6 and 1 2  
months. Compl ications and additiona l  treatments were registered in the hospita l fi les. 
Restenosis was defined as a peak systol ic velocity (PSV) ratio >2.5, as measu red on 
u ltrasound .  An occlus ion was defined as absence of flow in the treated segment of the 
superfici a l  femora l a rtery. 
Treatment protocol 
Procedures were performed using antibiotic prophylaxis with cephazol in 1 000 mg 
intravenously. The common femora l  a rtery was approached percutaneously using 
u ltrasound-guided or surgica l ly, in  an antegrade fashion according the surgeons' 
preference. When there was a concomitant lesion in  the common or profunda femoral 
a rtery an endarterectomy was performed. Heparin  (5000 IU) was admin istered. The 
diseased segment of the SFA was passed using  a Terumo® wire (Terumo Medica l 
Corporation, E lkton, M D) and a catheter, either endolumina l  or subintima l ,  and a re-entry 
was created dista l ly. The segment was pre-di l ated with a regu lar  angioplasty ba l loon and 
the endografts were positioned from d ista l to proximal  with min imal  oversizing.  The entire 
d iseased segment was covered with endografts and endografts were postdi lated with an 
angioplasty ba l loon with the same size as the endograft. Control angiography of the 
bypass and outflow vessels was performed routinely. In case of a percutaneous approach, 
the access was c losed using a closu re device (Angio-Seal ™ , St Jude Medica l ,  M N) .  
Use of endografts after failed AK femoropopliteal bypass I 99 
The used endograft was the heparin-bonded Viabahn Endoprosthesis r,N.L. Gore & 
associates, Flagstaff, Al), which is a self-expanding helical nitinol stent covered with a 
heparin-bonded thin ePTFE tube. 
After the procedure patients received statin treatment and dual anti-platelet inhibitors for 
1 year, unless oral anticoagulation was indicated for other reasons. 
Resu lts 
During the study period a total of 74 patients were treated with ePTFE-covered stents 
for SFA occlusive disease. Results from the RHA cohort have been described recently9• 
Five (7%) patients that had been treated before with an ipsilateral surgical bypass were 
identified. Four of them were male and one female. The median age was 60 years (range 
52-74 years). Cardiovascular risk factors included smoking (3/5), hypertension (4/5), 
dyslipidemia (3/5), diabetes mellitus (4/5) and cardiac history (4/5). One patient had 
undergone a kidney transplantation and the median glomerular filtration rate was 72 m U  
min (range 63-87 mUmin). 
Saphenous vein was used for the initial femoropopliteal reconstruction in three patients 
and a synthetic conduit in 2. The distal anastomosis was always in the above-knee area. 
Three bypasses were left-sided and 2 right-sided. The median time frame between 
initial femoropopliteal reconstruction and failure was 4.8 years (range 0.3-10.2 years). 
In 4 patients the entire bypass was occluded and in the remaining patient there was 
an occlusion of the popliteal artery immediately below the distal anastomosis, requiring 
reintervention. 
The indication for intervention was Rutherford category three in all patients and the 
median ankle-brachia! index (ABI) was 0.68 (range 0.46-0.85).The lesion was classified as 
TASC II C (n=1) and D (n=4). The median lesion length was 34 cm (range 8-38 cm) and the 
diameter of the popliteal artery was 5 .5  mm (range 5.2-6.0 mm). The popliteal artery was 
patent above the upper border of the patella (P1) in three patients and below the tibial 
plateau (P3) in two. In two patients the SFA was occluded flush from the origin. Three 
patients had three and two patients had two crural outflow vessels. 
Two patients were operated using general anesthesia, two using regional anesthesia and 
in one patient only local anesthesia was used. The use of spinal or general anesthetics 
I 
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enabled a conversion to a surgical bypass within the same session, in case of a technical 
failure of the procedure. Three patients were treated percutaneously, and in two patients 
the common femoral artery was dissected. In one of them an additional endarterectomy 
with patch was performed. In all patients the passage was subintimal without using re-entry 
devices, and in all patients the endografts (heparin-bonded Viabahn Endoprosthesis, W.l. 
Gore & associates, Flagstaff, AZ) were successfully inserted. In 1 patient 1 endograft was 
used, in two patients two endografts and in the remaining two patients three endografts 
with a diameter of 6 mm (n=4) and 7 mm (n=1). The median operation time was 76 
minutes (range 60-180 minutes), the used contrast medium 105 ml (range 80-195 ml) 
and the fluoroscopy time was 13 min (range 11-14 min). 
The postoperative course was uneventful in all patients. Specifically, no wound healing 
disturbances or postoperative edema occurred. Patients were discharged on the second 
postoperative day (range 1-5) with the two patients undergoing a hybrid procedure 
staying longest, respectively three and five days. The median ABI had increased to 0.95 
(range 0.70-1.18). The thirty-day morbidity and mortality rates were zero. 
Follow-up was available for all patients and the median follow-up was 18 months (range 
7-29 months). During follow-up all but one endograft remained patient. One patient 
needed a thrombectomy for an acute occlusion 40 days after insertion and remained patent 
afterwards. In one other patient routine duplex control demonstrated an asymptomatic 
occlusion of the endografts 12-months after insertion. Due to his good clinical condition 
patient was refrained from re-intervention. The Rutherford classification had increased 
from category 3, with a walking distance of less than 1 00m before the procedure to 
category 2, with a walking distance of 400m after failure. His walking distance further 
improved following walking exercise. During follow-up there were no minor or major 
amputations. 
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Figure 1 a and b. 
Pre-procedureal angiography from a 
57-year old male patient suffering from 
Rutherfort category three showing a 
38 cm long TASC II D lesion of the su­
perficial femoral artery. Patient, with a 
history of smoking, hypertension and 
dyslipidemia, had been treated with a 
venous above-knee femoropopliteal 
artery 6 years earlier. Arrow pointing at 
the proximal and distal anastomosis, 
respectively. 
Figure 2a and b. 
Post-procedural angiography, after per­
cutaneuous insertion of an endoluminal 
bypass using three 6mm endografts 
(15, 15 and 10 cm long heparin-bonded 
Viabahn Endoprothesis, W L. Gore & as­
sociates, Flagstaff, AZ) showing a patent 
endoluminal bypass with unaffected 
outflow vessels. 
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Discussion 
In the present paper we have shown that an endovascu lar  approach using endografts 
after fa i led femoropopl itea l bypass surgery is feasib le and safe for long chron ic occl usive 
lesions of the SFA. Although the present study inc l udes only few patients and fol low­
up is l im ited , our data suggest that this strategy cou ld be a va l id a lternative for redo 
femoropopl itea l bypass surgery. Although larger series wou ld provide a h igher level of 
evidence, the combination of a fa i led above knee bypass, an ind ication for re-intervention 
and a suitable anatomy for endovascu lar  treatment seems to be uncommon . In our series, 
only 7% of patients treated with an endograft had been previously operated, compl icating 
comparative studies with surg ica l re-intervention. 
In  an attempt to reduce postsurg ica l compl ications, due to the dissection of a previously 
operated gro in ,  Ascer et a l  have suggested a preferentia l  use of the external i l iac artery 
as an inflow source 10• After a mean fol low-up of 1 4  months, 25 out of 29 popl itea l 
bypasses were patent, whi le only superficia l  wound i nfection occurred at the below-knee 
popl iteal incision . As a min ima l ly invasive a lternative, Constanza et a l .  have stud ied the 
results of surgical thrombectomy and translumina l  ba l loon angioplasty for fai led above­
knee femoropopl itea l bypass grafts1 1 • In their  series, surg ica l thrombectomy a long with 
angioplasty, however, had an unacceptably h igh rate of fa i l u re and l imb loss in patients 
treated for early (<2 yea rs) bypass th rombosis .  Surgica l  graft revision or redo bypass was 
recommended to achieve successful revascu larization in these patients. In the present 
study we have successfu l ly treated 5 patients using endografts to create an endol umina l  
bypass after fa i led femoropopl iteal bypass surgery. There were no postoperative 
compl ications and the previously performed su rgica l  procedu re did not compl icate 
various steps of the endovascu lar  procedure, inc luding access, subintima l  dissection,  
creation of the re-entry, deployment of the endografts and closu re of the puncture site. 
Their observation supports the hypothesis that an endovascu lar approach is feasible 
fol lowing previous surgica l procedu res and emphasizes that the dissection of a previous 
operated groin cou ld be avoided. 
The place of endografts in the a lgorithm of atherosclerotic d isease of the SFA is sti l l  under 
debate. In  primary procedures the patency rates a re comparable with prosthetic surg ica l 
bypasses8 , often used in redo surgery. The technique, however, might a lso be considered 
as a bridge to surgery, preserving vein and preventing sca r formation, related to increased 
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morbidity at secondary interventions. On the other hand, it may be considered as a way 
out for those unfit for surgery or as the technique of choice for those with failed surgery, 
such as in our patients. 
In one of our patients the endograft occluded within the first postoperative year. Due to a 
good clinical condition, with a Rutherford classification that had increased from category 
3 before the procedure to category 2 after failure, no re-intervention was performed, 
indicating that an endovascular strategy may postpone surgery in an often frail group 
of patients. Conclusions on the long-term performance of the endoluminal bypass after 
failed surgery may not be drawn from the present data, due to the small sample size. 
Patency rates, however, might be lower when compared to primary procedures as seems 
to be true for surgical bypasses. In a series of 112 prosthetic bypasses, Aune et al. have 
shown that results of redo procedures are inferior to those of primary procedures1 2 • 
Adequate outflow and diameter of the popliteal artery seem to be important parameters 
for clinical success of an endovascular strategy. Studies with a larger sample size are 
indicated to clarify the performance of an endoluminal bypass after failed surgical or 
endovascular treatment using bare metal stents. 
In conclusion, we have shown that the creation of an endoluminal bypass using endografts 
after failed femoropopliteal bypass surgery is feasible and safe and could be used to 
avoid or minimize the difficult and hazardous dissection of a previously operated area. I 
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Abstract 
Introduction 
The endolumina l  femoropopl itea l bypass is a min ima l ly invasive treatment moda l ity 
for occlusive superficia l  femoral artery disease. Technica l  fa i l u re of endovascu lar  
treatment of chronic tota l occlusions a re often caused by the inabi l ity to re-enter 
the true l umen. Re-entry devices have a h igh technica l  success-rate, but increase 
procedu ra l  costs. We describe an a lternative technique using an ipsi latera l combined 
antegrade-retrograde approach to insert an endo lumina l femoropopl itea l bypass. 
Technique 
In a supine position, with the leg 30-degrees e levated, the popl iteal artery is 
punctured and a 4-french introducer sheath is introduced . The occlusion is crossed 
from d ista l  to proxima l  and the wire is advanced through a 6-french sheath that is 
positioned in the common femora l  a rtery. The occlusion is pre-d i lated from proximal  
and the ' re-entry' site is identified on an angiogram .  The wire is then withdrawn into 
the ba l loon catheter and advanced intra lumina l ly into one of the crura l  vessels. After 
confirming the intra lumina l  position of the wire, the 4-french sheath is removed, and 
the endolumina l  bypass is created in a standardized fashion . 
Conclusion 
The ips i latera l antegrade-retrograde approach is a fast, cheap and easy-to- learn 
technique, using standard materia ls only . The d ista l entry of the occlusion wi l l  lead 
to a min im ization of the length of the endolumina l  bypass, thereby possibly sparing 
co l l atera l s  and futu re surgica l  options. 
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I ntroduction 
The endoluminal femoropopliteal bypass i s  slowly gaining popularity for the treatment 
of long chronic occlusions of the superficial femoral artery. In a randomized controlled 
trial , McOuade et al. have recently shown that the management of superficial femoral 
artery occlusive disease with percutaneous endografts has a similar primary patency at 
4-years when compared to conventional femoral popliteal artery bypass grafting using 
a synthetic conduit1 • Limb salvage rates were also comparable. The percutaneous 
technique is considered to be associated with lower morbidity compared to open bypass 
surgery, due to its minimal invasive character. The role of endografts in the treatment 
algorithm of occlusive disease in superficial femoral artery, however, remains a matter of 
debate. Recently, Boufi et al. observed in a retrospective study in 54 limbs that combining 
subintimal angioplasty with an endograft in femoropopliteal lesions did not improve 
patency when compared to angioplasty only2 • These data, however, are in contrast with 
the observations of Saxon et al. , who found in a prospective multicenter randomized study 
that the use of an endograft was correlated to a significantly higher technical success rate 
(95% vs. 66%) and 1-year primary vessel patency rate (65% vs. 40%)3. A patency benefit 
was seen for those lesions longer than 3 cm and at 12 months the chronic limb ischemia 
status was 15% further improved for the endograft group. 
Technical failure of endovascular treatment of chronic total occlusions is most often 
caused by the inability to re-enter the true lumen after the occlusion is crossed in a 
subintimal plane. The incidence of technical failure due to the inability to re-enter the 
true lumen using standard catheter and wire techniques may vary between indications 
and centers but may be as high as 26%4 • In case of technical failure there are various 
alternative approaches, including the use of re-entry devices. We describe a technique 
using an ipsilateral combined antegrade-retrograde approach to insert an endoluminal 
femoropopliteal bypass. 
Surgica l technique 
Between January 201 0  and April 201 1 four patients were treated with the ipsilateral 
antegrade-retrograde approach to insert an endoluminal femoropopliteal bypass for 
l 
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peripheral arterial disease. All were in the third category according to Rutherford and had 
a TASC-1 1  D lesion. The indication for this approach was always the inability to re-enter 
the healthy lumen of the femoropopl i teal artery using standard antegrade techniques. 
Preoperatively, patients received 5000 I.U. heparin and 1 gram cefazolin intravenously. In 
all patients the common femoral artery was punctured using ultrasound and a 6-french 
i ntroducer sheath was inserted onto the superficial femoral artery. Then , the occlusion was 
crossed using a Terumo® wire (Terumo Medical Corporation , Elkton , MD) and a catheter. 
When various attempts to re-enter the true lumen had failed, an OUTBACK® LTD® re-entry 
device (Cordis Corporation , Bridgewater, NJ) was tried in one patient unsuccessfully. 
Then , the approach was converted into the ipsilateral antegrade-retrograde approach. In 
a supine position , the leg was elevated 30 degrees in the hip in  a stable position using a 
sterile support. The popliteal artery was punctured in a dorsal approach using ultrasound 
in three patients and using fluoroscopy in combination with a roadmap in one patient 
and a 4-french introducer sheath was placed. Using the Terumo® guide wire the occlusion 
was crossed again (fig 1 )  and proximally the wire was advanced into and through the 
6-french sheath in the common femoral artery, thereby creating a 'body floss' (fig 2). 
Subsequently, the occlusion was pre-dilated with an angioplasty balloon. The re-entry 
site was identified on an angiogram made through the 4-french sheath. Then the wire 
was withdrawn into the balloon catheter, leaving the 4-french introducer sheath in place, 
and advanced intraluminally into one of the crural vessels (fig 3). After confirming the 
i ntraluminal position of the wire, the 4-french sheath was removed, providing hemostasis 
using compression , and the endoluminal bypass was created in a standardized fashion 
using heparin-bonded ePTFE-covered stentgrafts (Viabahn® , W.L. Gore, Flagstaff, AZ, 
USA (Fig 4)). Angiography showed a good deployment of the endografts and outflow. In 
one patient an additional stentgraft had to be placed distally to cover a dissection close 
to the distal edge of the bypass. The 6-french sheath was removed from the common 
femoral artery and the puncture site was closed using a closure device (Angio-Seal™ , 
St. Jude Medical, St. Paul, MN). There were no bleeding complications and all patients 
were discharged from the hospital the first postoperative day. During follow-up, varying 
between 1 and 7 months, all bypasses remained patent. 




Figure 1 .  
The leg is elevated 3 0  degrees and 
the popliteal artery is punctured. 
Subsequently a 4 french introducer 
is placed and the occlusion is passed 
subintimally. 
Figure 2. 
The wire is extracted through the 6 
french introducer sheath in the com­
mon femoral artery. 
Figure 3. 
Following pre-dilatation the distal 
end of the wire is positioned in a se­
cure position in the crural vessels. 
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Discussion 
In all 4 treated patients the ipsilateral antegrade-retrograde approach proved to be a 
fast and successful technique and no complications of the additional popliteal puncture 
occurred. There are multiple advantages of the combined antegrade-retrograde technique 
for re-entering the true lumen distal from a chronic occlusion of the superficial femoral 
artery. First, the technique is easy to learn and the popliteal artery may be punctured 
using either ultrasound or fluoroscopy using standard techniques. Second, because the 
occlusion is entered distally, the distal 're-entry' site will always be as proximal as possible , 
which will minimize the length of the endoluminal bypass. As a consequence, collaterals 
may be spared and in case of an occlusion of the bypass all surgical options will remain 
available. Third, although the use of re-entry devices, such as the Outback catheter, 
is related to a high procedural success of 88-96% and a low complication rate, these 
devices increase procedural costs5·6. Since in the here described technique only standard 
materials are used the technique is extremely cheap when compared to the use of these 
re-entry devices. 
A retrograde transpopliteal recanalization of the superficial femoral artery has previously 
been described. In a series of 56 patients, in which an antegrade subintimal angioplasty 
could not be completed due to re-entry failure, they described a 98% success rate using a 
retrograde technique using a bare metal stent in 71 % of cases. An inconvenience of their 
technique is that patients should be turned from a supine into a prone position during 
treatment7 • Recently, Lesperance et al. have described a technique for the retrograde 
stentgraft angioplasty of a superficial femoral artery occlusion8 • Disadvantage of this 
retrograde technique is the necessity to place a 6- of 7-french sheath into the popliteal 
artery. Therefore , they opted for an open above-knee popliteal artery exposure. Since 
in our technique only a 4-french introducer sheath is inserted no popliteal dissection is 
necessary and the technique will remain strictly percutaneous. Recently, Kawarada and 
Yokoi have published a case report, using a similar technique as we used in our patients9• 
They successfully treated the occluded segment using a bare metal stent that was placed 
in an antegrade fashion. 
The role of covered stents in the treatment algorithm of occlusive superficial femoral 
artery disease is still a matter of dispute. During the study period, all patients in our 
center with a lesion length of over 10 cm were preferably treated with an endograft when 
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an endovascular treatment strategy was chosen. Since October 2010, these patients 
are included in the multicenter randomized SuperB trial (NCT01220245), comparing a 
heparin-bonded endograft with the current gold standard for long lesions, the venous 
femoropopliteal bypass. 
Conclusion 
The ipsilateral antegrade-retrograde approach is a fast , cheap and easy-to-learn 
technique. The distal entry of the occlusion will lead to a minimization of the length of the 
endoluminal bypass, thereby possibly sparing collaterals and surgical options. 
I 
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Abstract 
Background 
Endovascu lar  treatment options for the superficia l  femora l artery are evolving 
rapidly. For long lesions, the venous femoropopl itea l  bypass is considered to 
be superior above the prosthetic bypass. An endo lumina l  bypass, however, may 
provide equal patency rates compared to the prosthetic above knee bypass. The 
introduction of heparin-bonded endografts may further improve patency rates. The 
SUrgical versus PERcutaneous Bypass (SuperB) study is designed to assess whether 
a heparin bonded endo lumina l bypass provides equa l  patency rates compared to 
the venous bypass and that it is associated with improved qua l ity of l ife, related to 
a decreased compl ication rate, or not. 
Methods/design 
Two-hundred-twenty-two patients with periphera l  arteria l  occlusive d isease, 
category 3-6 according to Rutherford, wi l l  be randomized in two treatment arms; 1 .  
the surgica l femoropopl itea l bypass, venous whenever possib le ,  and 2. the heparin­
bonded endo lumina l  bypass. The power ana lysis was based on a non-inferiority 
principle, with an effect size of 90% and 1 0% marg ins (a lpha 5%, power 80%). 
Patients wi l l  be recruited from 5 teaching hospita ls in the Netherlands during a 2-year 
period . The primary endpoint is primary patency and qua l ity of l ife (eva luated by 
the RAND-36 questionnaire and the Wal king Impa i rment Questionnaire). Secondary 
endpoints include secondary patency, freedom-from-TLR and compl ications. 
Discussion 
The SuperB tria l  is a mu lticentre randomized contro l led tria l  designed to show 
non-inferiority in patency rates of the heparin-bonded endograft compared to the 
surgica l bypass for treatment of long SFA lesions, and to prove a better qua l ity of 
l ife using the heparin bonded-endograft compared to surg ica l ly treatment, related 
to a reduction in com pl ications. 
Tria l  registration: C l in ica ltria ls  NCT01 220245 
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Background 
In the treatment of long lesions of the superficial femoral artery (SFA) the surgical venous 
bypass is considered the gold standard1 • Bypass surgery, however, is associated with 
complications and a prolonged hospital length of stay. Endovascular techniques have 
advanced and provided new treatment options for peripheral vascular disease, but may 
also induce complications as was shown in the Basil trial2 • Last few years evidence has 
been accumulating that the treatment of long lesions with (covered) stents may provide 
acceptable short- and midterm primary patency rates, as summarized in several recent 
reviews3-7 • 
Randomized trials have shown that 1-year patency rates of self-expanding nitinol metal 
stents vary between 70-90% as recently summarized by Lin et al5 • Despite improvements 
in stent design and introducer sizes, one of the major issues limiting patency is in stent 
restenosis. It was recently demonstrated that with the use of covered stents, restenosis is 
reduced to edge stenosis only8 • The efficacy of an ePTFE-covered nitinol stent (Viabahn, 
W. L. Gore, Flagstaff, AZ, USA) in treating chronic SFA long lesions, over 8 cm in length, 
is currently being compared to bare nitinol stents in a multicentre randomized controlled 
trial (VIBRANT trial). The study hypothesis is that the use of ePTFE-covered nitinol stents 
will result in greater mid-term (24 months) and long-term (36 months) patency. Although 
interim analysis has shown no significant differences at one-year, final results have to be 
awaited. Recently, the 4-year results of a randomized trial have been published comparing 
an ePTFE-covered nitinol stent with the above-knee ePTFE femoropopliteal bypass9 • The 
1-year and 2-year patency rates were 73% and 74%, and 63% and 64%,  respectively1 0, 1 1 • 
At 4-year follow-up, the primary patency rates were 59% and 58% respectively, and limb 
salvage rates were also comparable. When compared to a prosthetic bypass , however, 
the venous bypass has better patency rates, with 1-year and 4-year primary patency rates 
of 87% and 70% , respectively. There are patient groups with long lesions of the SFA, 
especially patients with severe co-morbidities, that might benefit from a less invasive 
treatment strategy. The risk of wound complications, limb edema, loss of the great 
saphenous vein, and cardiac complications may have to be taken into account when 
deciding to treat surgically or endovascularly. 
Heparin-bonded prosthetic bypass grafts have shown improved patency rates in animal 
models and non-randomized clinical trials1 2· 13· 1 4 • Recently, the heparin-bonding technology 
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has been integrated with i n  the Viabahn endograft. Using this techn ique resu lts may 
further  improve to the level of the current gold standard;  the venous femoropopl itea l 
bypass. Advantages of the endolum ina l  techn ique wou ld be related to its min ima l  
invasive character: less pa i n ,  earl ier recovery and less early compl ications. To date, no 
stud ies h ave been performed to compare the use of heparin-bonded endografts for the 
treatment of long lesions of the SFA. The cu rrent study has been designed to compare 
the use of hepa rin-bonded endografts for the treatment of long lesions of the SFA to the 
venous surg ica l femoro-pop l itea l  bypass in a mu lticentre randomized control led tria l .  
Methods and design 
Study design 
The design  of the study is a mu lti centre prospective randomized control led tria l  comparing 
the patency of the heparin-bonded endograft to the venous surgica l bypass. Endpoints 
a re primary patency after 1 ,  2 a nd 5 years, compl ications and qua l ity of l ife . 
Study objectives 
The a im  of the study is to demonstrate that the heparin-bonded endograft provides equal 
patency rates compared to the venous surg ica l femoropopl itea l  bypass. In addition we 
hypothesize that patients receiving a heparin-bonded endograft show better qua l ity of 
l ife at 30-days compared to patients who were surg ica l ly treated. 
Sample size calculation 
The assumption has been made that the hepari n-bonded endolumina l  bypass wi l l  have 
a s im i la r  cumulative primary patency at one year  compared to the autologous venous 
surgica l  bypass. For a non-inferiority tria l  with an  effect size of 90% and a margin of 1 0%, 
1 1 1  patients per group are needed (a lpha 5%, power 80%) . The effect size of 90% refers 
to an estimated patency rate at one year in the surgica l  control arm. 
The assumption has been made that the hepari n-bonded endolumina l  bypass wi l l  have 
an increase in OOL, as measu red by a 1 0-point increase in the SF-36 score, at 30 days 
fo l low-up .  With a standard deviation of 20, 63 patients per group are needed (a lpha 5%, 
power 80%). 
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Significance will be tested with the Student-t test (normal distribution) of Mann Whitney 
U-test (skewed distribution). 
Setting 
Patients will be recruited from the following centers: Rijnstate Hospital, Arnhem; lsala 
Clinics, Zwolle; Nij Smellinghe Hospital ,  Drachten; Antonius Hospital , Sneek; University 
Medical Center Groningen , Groningen, The Netherlands. In each of the participating 
centers, each surgeon performing the endovascular procedure must have placed at least 
ten endoluminal bypasses prior to treating patients who participate in the SuperB trial to 
prevent a learning curve bias. 
The total study duration will be 7 years; the recruitment period will take 2 years and 
thereafter patients will be evaluated yearly until 5 years post-procedure. 
Primary endpoints 
The primary endpoints of the study are the primary patency at 1 -year follow-up. In 
addition the quality of life, using the RAND SF36 Questionnaire, will be evaluated as a 
primary endpoint. 
Secondary endpoints 
1. Secondary patency 
2. Complications 
3. Clinical improvement 
4. Surgical and endovascular re-interventions 
5. Target lesion revascularization 
6. Additional ly an exploratory, thus hypothesis generating, subgroup-analysis will be 
performed. 
- Patients with disabling intermittent claudication (Rutherford 3) wil l  be analyzed 
separately using pain-free and maximal walking distance and the Walking 
Impairment Questionnaire as additional endpoints. 
- Patients with ischemic rest pain and necrosis (Rutherford 4-6) will be analyzed using 
major amputations as an endpoint. 
• • 
122 I Chapter 8 
Ethical considerations 
A patient who meets the entry criteria is ful ly  informed about the trial and provided with 
a patient information and consent form. Patients willing to participate in the study are 
included after signing the informed consent form. This study is conducted in accordance 
with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. 
The study is approved by the Medical Ethics committee of Nijmegen (CMO 2010-089) 
and the local institutional board of each participating center. 
Safety and quality control 
Data Safety Monitoring Board 
The Data Safety Monitoring Board (DSMB) will review safety and makes recommendations 
regarding the conduct of the study to the steering committee and to the accredited 
Medical Ethical Board (METC) that approved the study protocol. An interim safety analysis 
will be performed at 1-year after initiation of the trail. This analysis will include at least 40 
patients. 
Adverse and severe adverse events 
Adverse events (AE) are defined as any undesirable experience occurring to a participant 
during the study, whether or not considered related to the investigational device. This 
definition includes events occurring during hospital stay up to 30 days of follow-up. 
Underlying disease that was present at the time of enrollment is not reported as an AE,  
but any increase in the severity of the underlying disease will be reported as an AE. All 
AEs will be monitored from the time of enrolment through the 30-day follow-up visit. AEs 
wil l be recorded on the case record forms (CRFs). A description of the event, including the 
start date, end date , action taken , and the outcome will be provided. 
A severe adverse event (SAE) is any event leading to death, major amputation or definitive 
graft failure. 
Data on AEs will be reported to the DSMB and to the accredited METC via "Toetsingon line" 
on the website of  the Central Committee on Research involving Human Subjects (CCMO, 
ccmo.nl). 
Inclusion criteria 
Patients over 1 8  years of age 
Informed consent 
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De novo stenosis, re-stenosis (Peak Systol ic Velocity (PSV) ratio>2 .5) or occlusion of 
the native SFA, a l l  > 1 0cm in length 
Popl itea l artery is patent at the upper margin of the pate l la  to the trifurcation 
Diameter of the native SFA and popl itea l arteries a re 5.0 to 7 . 5  mm 
Rutherford category 3-6 
Ind ication for surg ica l bypass 
Dista l runoff at least 1 crura l  vessel without sign ificant stenosis 
Resting ankle-brach ia !  index (ABI) <0.8 in the study l imb prior to procedu re 
Exclusion criteria 
Patient unsuitable for admin istration of contrast agent 
Pregnancy 
Dementia or a ltered menta l status that wou ld proh ibit g iving conscious informed 
consent 
Need for adjunctive major surgica l  or vascu la r  procedures with in 1 month 
Untreated flow- l imiting aorto-i l iac occlusive disease 
Unsuccessfu l ips i latera l percutaneous vascu la r  procedu re to treat inflow d isease just 
prior to enro l lment 
Previous ipsi latera l  bypass surgery or stentplacement 
Femora l  or popl itea l  aneurysm of target vessel 
Non-atherosclerotic disease resu lting in occlus ion (e.g .  embol ism, Buerger's disease, 
vascu l itis) 
Severe medica l co morbidities (untreated coronary artery d isease /congestive heart 
fa i l u re, severe chronic obstructive pu lmonary d isease, metastatic ma l ignancies, 
dementia ,  etc.) or other medical condition that wou ld prec lude compl iance with the 
study protocol 
Major d ista l amputation (above the trans metatarsa l) in the study l imb 
Any previously known coagu lation d isorder, inc luding hypercoagu labi l ity 
Contraindication to anticoagu lation or antip latelet therapy 
Known a l lerg ies to stent or endograft components 
• • 
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History of prior life-threatening reaction to contrast agent 
Patients with known hypersensitivity to heparin, including those patients who have 
had a previous incidence of heparin-induced thrombocytopenia (H IT) type II 
Planned surgical procedure or major amputation to occur after enrollment of the 
patient 
Recruitment 
Patients with symptomatic peripheral arterial disease of the superficial femoral artery with 
a Rutherford category 3-61 5  may be included in the study and will be recruited among the 
5 participating centers. 
Randomization 
Randomization will be performed during the out patient department visit in which the 
patient is included. The including physician will call the telephone number provided by 
the principle investigator. The person answering the phone will draw an envelope from 
a box of plain white envelopes containing the randomization choice. The envelopes are 
divided in batches of 20 and randomization is stratified by center. 
Imaging 
All patients included in the study are screened by ultrasound imaging. Additionally, 
computed tomography angiography (CTA) or magnetic resonance angiography (MRA) 
will be performed. These imaging studies will be performed according to the local 
protocol of the participating centers. The lesions in the SFA will be categorized according 
to the Trans Atlantic lntersociety Consensus (TASC)-1 1  criteria. Type B, C, and D lesions 
may be included. 
Treatment details 
Endovascular technique 
Antibiotic prophylaxis is administered. Preferably a percutaneous technique is used, but 
in case of a flush occlusion or a diseased common femoral artery, an open approach 
is allowed. The SFA may be approached in a contralateral retrograde or an ipsilateral 
antegrade fashion. When there is a concomitant lesion in the common or profunda 
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femoral artery an endarterectomy may be performed followed by the endoluminal 
bypass. Heparin (5000 I .U.) is administered. The diseased segment of the SFA is passed, 
either endoluminal or sub-intimal and a re-entry is created distally. The segment is pre­
dilated with a regular angioplasty balloon and the endografts are positioned from distal 
to proximal without or with minimal oversizing. The entire diseased segment is covered 
with the stentgrafts and the stentgrafts are postdilated with an angioplasty balloon with 
the same size as the stent graft. Control angiography is performed routinely and the 
access is closed using a closure device , according to local protocols. 
The used endograft is the heparin-bonded Viabahn Endoprothesis r,N.L. Gore & 
associates, Flagstaff, AZ), which is a self-expanding helical nitinol stent covered with 
a heparin-bonded thin polytetrafluorethylene (ePTFE) tube. The size of the stentgraft 
should be at least 6 mm. 
Post procedurally, all patients will be treated with acetylsalicylic acid 80 mg and clopidogrel 
75 mg for the first year unless oral anticoagulation is indicated for other reasons. After 
1 year patients may be switched to one thrombocytaggregation inhibitor. All patients 
receive statin treatment, started before the intervention. 
Open surgical technique 
The surgical femoropopliteal bypass is performed according to local protocols. Preferably 
the greater saphenous vein is used as conduit in all patients. The used vein has a diameter 
of at least 3 . 5  mm. Pre-operative vein mapping may be performed, but is not obligatory. 
When the great saphenous vein is unavailable or unsuitable a prosthetic graft may be 
used. When a prosthetic conduit is used the participating surgeon will explicit this choice. 
All patients will be included in the intention-to-treat analysis. 
Post procedurally, all patients will be treated with acetylsalicylic acid 80 mg and clopidogrel 
75 mg for the first year unless oral anticoagulation is indicated for other reasons. After 
1 year patients may be switched to one thrombocyt aggregation inhibitor. All patients 
receive statin treatment, started before the intervention. 
Fol low-up 
Follow-up is planned at 1 ,  3 and 6 months. Afterwards patients will be seen each 6 months 
until 2 years. From 2 to 5 years patients will be evaluated annually. Duplex ultrasound 
imaging, ankle-brachia! indices, and OOL scores will be measured at all above mentioned 
• • 
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time points. All primary and secondary endpoint are registered as defined in the study 
protocol. 
QOL scores 
RAND-36 is a multidimensional measurement of health. This will be used in both 
groups 
W IQ (Walking Impairment Questionnaire) is especially designed for patients with 
claudication, and will only be used in patients treated for claudication. 
These scores are taken prior to the intervention and at defined times afterwards (i.e. 
1 day, 1 week, 1 month, etc). 
Data collection 
Data will be collected at the recruitment centre by means of case report forms (CRF's). The 
copies of the CRF forms will be sent to the coordinating center (Rijnstate Hospital) where all 
data will be entered in the central database and controlled by an independent monitor. The 
participating centers will be informed about the current status of recruitment and adverse 
events via a newsletter every 3 months. Additionally, there will be regular contact between 
the principle investigator and the contact persons from the participating centers. 
Statistical analyses 
Data concerning the 1, 2 and 5 year follow-up will be analyzed for both study groups in 
an intention-to-treat and a per-protocol manner by student t-test (normal distribution) of 
Mann Whitney U-test (skewed distribution). Corrections will be made for study centre. 
Additionally, in case of sufficient numbers, the data will be analyzed for different TASC 
II categories; otherwise the analyses will be additionally adjusted for TASC II categories. 
Patency rates will be presented as Kaplan Meier curves including censoring. 
Publication of data 
Data will be published after a follow-up period of 1, 2 and 5 years, regardless of the 
outcome of the study under the responsibility of dr. MMPJ Reijnen. Co-authorship will 
be assigned according to the 'Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals: Writing and Editing for Biomedical Publication' of the International 
Committee of Medical Journal Editors. 
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Definitions 
Procedura l  success: 
- Endovascu lar - Successfu l vascu lar  access, exact deployment of the device and 
completion of the endovascu lar procedure and immediate morpholog ica l effect 
(< 30% residua l  stenosis) 
- Surgica l - Successfu l access, completion of surg ica l procedure and c l i n ica l ly 
assessed immed iate improvement 
Primary patency: The absence of occlusion or flow-l imiting stenosis (PSV ratio 
>2.5) of the treated segment of the artery inc luding 1 cm proximal and d ista l of 
the anastomosis, as documented by accepted imaging techniques, particu larly 
a rteriography or duplex u ltrasonography, or d irect observation at operation or 
postmortem. 
Primary assisted patency: When a secondary endovascular or open procedure is 
performed to prevent fa i l u re, i .e. in a flow reducing stenosis (PSV ratio >2.5), in a sti l l­
patent segment of the stent graft or bypass, inc luding the anastomoses. 
Secondary patency: When a thrombolytic or surg ica l treatment has been performed 
for graft or stent graft occlusion in an afterwards patent vessel .  
Target lesion revascu larization :  Repeat percutaneous o r  surgica l revascu larization 
driven by cl in ical state in the presence of a flow reducing stenosis or occl usion in the 
treated segment of the a rtery inc luding 1 cm proximal and dista l of the anastomosis. 
Type B lesion SFA accord ing to TASC II criteria :  
- Mu ltiple lesions (stenosis or  occlusions) ,  each $; 5 cm 
- Sing le stenosis or occlusions $; 15  cm (not involving infragenuale popl iteal segment) 
- Heavily ca lcified occlusion $; 5 cm in length 
- Single popl iteal stenosis 
Type C lesion SFA accord ing to TASC I I  criteria :  
- Mu ltiple stenosis or occlusions tota l ing > 15  cm with or without heavy ca lcification 
- Recurrent stenosis or occlusions that need treatment after 2 endovascu lar 
interventions 
Type D lesion SFA accord ing to TASC I I  criteria :  
- Chronic total occ lusions of CFA or SFA (>20 cm, i nvolving the popl iteal a rtery) 
- Chron ic tota l occlusions of popl iteal artery and proximal trifurcation arteries 
Minor amputation: Below the ankle amputation, planned or unplanned . 
I 
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Major amputation: Above the ankle amputation, planned or unplanned 
Clinical improvement: Improved Rutherford classification compared to baseline. 
Intermediate lesion: Occlusion or stenosis > 10 cm length 
Flow-reducing (re-)stenosis: A stenosis with a PSV ratio of more than 2.5 as measured 
by duplex, or a >50% (re-)stenosis on angiography, MRA or CTA. 
Graft failure: Definitive occlusion of the bypass with unsuccessful thrombolytic or 
surgical treatment 
Re-intervention: Secondary percutaneous or surgical intervention of the bypass. 
Seroma: Non-infected fluid accumulation under the wound 
Hematoma: Accumulation of blood postoperatively in the operated area. 
Re-bleed: Accumulation of blood postoperatively requiring operative treatment. 
Abscess: Accumulation of pus in the operated area. 
Infected wound: Red, swollen, but closed wound, not requiring surgical drainage. 
Open wound: Non infected wound leaking fluid. 
Loss of sensibility: Postoperative clinical loss of sensibility of the skin in the operated 
leg. 
Femoral nerve damage: Clinical femoral nerve damage. 
Graft infection: Proven graft infection requiring long term use of antibiotics or graft 
removal. 
Edema: Postoperative persistent edema of the operated leg. 
Serious adverse event (SAE): An adverse event that leads to death or serious 
deterioration in the health of the subject, defined as death, definite failure of graft/ 
bypass or major amputation in the treated leg 
Discussion 
The aim of the present randomized trial is two-fold. First, it  aims to compare patency 
rates of the endoluminal bypass, combined with the heparin-bonded technology, with 
the current gold standard, the venous femoropopliteal bypass, the current gold standard. 
Second, it aims to demonstrate that an endovascular approach is associated with fewer 
complications and thus an improved quality of life. In order to have sufficient power, the 
trial was designed using a non-inferiority principle. 
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Data ana lysis wi l l  be performed in both an intention-to-treat as a per-protoco l manner. 
The first wi l l  be performed to compare the endolumina l  bypass with common su rgica l  
practice, namely that some patients w i l l  not have a vein  usable for the bypass and that 
some endolumina l  procedures wi l l  be converted to open surgery. The per-protocol 
ana lysis wi l l  g ive information about the performance of the endolumina l  bypass itself. 
There a re severa l differences between the Su perB tria l  and previously pub l ished 
randomized tria ls9• 1 6 • The SuperB tria l  is the first tria l  us ing a heparin-bonded endograft 
and the inclusion criteria a re chosen much broader since hybrid procedures, such as a 
reconstruction of the common femora l a rtery, are a l lowed. Moreover, the anti-platelet 
reg ime a nd the use of statins are standardized . The wide inc lusion criteria a re chosen 
because they mimic  common surgica l practice and thereby they reduce the risk on 
inclusion problems as was the case in  the Scandinavian tria l 16 • 
With the introduction of the heparin-bonded technology in the endograft the design of 
the stent has a lso been changed.  The proxima l edge of the endograft has no longer a 
stra ight, but a contoured edge. Th is adaptation wi l l  reduce info ld ing in case of oversizing,  
thereby mainta in ing laminar  blood flow and preventing intima l  hyperplasia and  thus 
edges stenosis. The expected effect of the new endograft may therefore not o n ly be 
attributed heparin-bonding technology. 
The SuperB tria l  hypothesizes that the treatment of the long lesion of the S FA with a 
heparin-bonded endograft wi l l  show equa l  patency rates compared to the surgical  
bypass, but a better qua l ity of l ife for treatment with the heparin-bonded endog raft is 
expected, related to a reduced morbid ity. Therefore, patients wi l l  be asked to fi l l  out 
the RAN D 36 questionna i re before treatment and at each visit during fol low-up.  Patients 
with interm ittent c laudication additiona l ly wi l l  be asked to fi l l  out the Wa l king Impa i rment 
Questionnaire at the same visits. Tria l s  on endolumina l  bypass inc luding qua l ity of l ife 
scores have not been performed, to date. 
In concl usion, the SuperB tria l  is a mu lticentre randomized contro l led tria l  des igned to 
show equa l ity in patency rates of the heparin-bonded endograft compared to the su rgica l  
bypass for treatment of longer lesions of the SFA, but to show better qua l ity of l ife using 
the hepa rin bonded-endograft compared to surgica l ly treatment, re lated to a reduction 
in compl ications. 
I 
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Figure 1. The Viabahn endograft (WL. Gore, Flagstaff, AZ, USA) with a contoured proximal edge. 
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General  d iscussion 
Since the development of the venous femoropopl itea l bypass by Kun l in  in 1 948, i t  has 
been the standard treatment moda l ity for long lesions of the superficial femora l  a rtery 
(SFA) 1 • Recent technica l  advances made endo lumina l  techn iques feasible after which 
the endograft treatment modal ity was added to to the treatment a lgorithm of ch ronic 
occ lusive disease . I n  the previous chapters we tried to define the exact role of this 
re latively new treatment modal ity. 
It goes without saying that the primary treatment of periphera l  a rteria l  disease (PAD) 
consists of best medical treatment2•3 . Antiplatelet and statin therapy are started at the 
onset of symptoms. Specifica l ly patients who present with intermittent c laudication 
( IC) gain advantage with exercise, i .e .  supervised wa lking tra in ing4•5·6 . I n  patients with 
ch ronic Rutherford category 3-6 su rgica l therapy can be considered if supervised wa l king 
tra in ing fai ls .  When opting for surg ical therapy, in case of longer lesions, the venous 
bypass is sti l l  the golden standard7 • This bypass has primary patency rates of 75% at five 
years8·9 . Surgica l  reconstruction however is re lated to h igh  morbid ity rates, including ea rly 
postoperative compl ications as wound hea l i ng distu rbances (5-44%)7 ·10  and edema (40%-
1 00%) 1 1 • 1 2. Surgica l  bypass is related to a fa i l u re rate of 1 0% to 20% at one-year fo l low-up, 
for a venous and prosthetic condu it, respective ly 13 • 
Endo lumina l  techniques can play a ro le  in both primary and secondary procedures 
(Chapter 2, Chapter 6). Percutaneous trans lumina l angioplasty (PTA) is a l ready considered 
the treatment of first choice with short lesions of the SFA1 . When treating longer lesions 
of the SFA (> 1 0cm) endolumina l ly, stenting is recommended 1 4· 1 5· 16. To prevent in stent 
restenosis due to neointimal hyperplasia after endol umina l  therapy in TASC-I I C/D lesions, 
these are preferably treated with a covered n it inol stent. Covered stents reduce restenosis 
to edge stenosis a lone 1 7, which is easier to treat than in stent restenosis. Severa l studies 
describe improved primary patency rates from 70%1 4• 15• 16 to 83%1 8• 1 9  with covered n itinol  
stent placement. Patency rates of non heparine-bonded endografts are comparab le with 
those of synthetic bypasses (two-year primary 63% vs 64% for bypass20).  
An endo lumina l  bypass offers several advantages. It is a min ima l  invasive a lternative in 
the often fra i l  vascu la r  popu lation. No major surgery is necessary. Endolumina l  stentgrafts 
can be placed either percutaneously or with an ingu ina l  incision . Th is procedure can be 
performed under loca l anesthesia .  The min ima l invasive character translates to a lower 
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complication rate. As described in chapter 3 our overall complication rate was 7 .5%. 
In our series no patients developed wound healing problems and only one developed 
postoperative edema. Another advantage of an endograft is the earlier postoperative 
recovery. After a venous bypass, patients are admitted an average of 5 days postoperatively 
(4.4-9.1 days2 1 •22). Our patients were admitted for less than three days and there were no 
intensive care unit admissions after endograft placement (Chapter 3). 
Primary use of an endoluminal bypass evades surgical bypass surgery in 89% of patients 
through patency or clinical improvement despite failure of the endograft (at 2-year 
follow-up, Chapter 4). And if an endograft fails, secondary surgical bypasses remain 
possible, with potentially the greater saphenous vein available as the endoluminal bypass 
preserves the autologous vein. Collateral loss after endograft placement has always 
been considered a disadvantage of the technique. The overstenting of collaterals might 
worsen the clinical state of patients after failure of the endograft. In Chapter 4 and 5 we 
describe the outcome of patients after failure of the endograft. In our study population 
the majority of patients returned to a similar or better clinical state after failure of the 
endoluminal bypass (43% improved, 37% equal Rutherford category). Limb salvage rates 
are excellent (94-100%) and secondary surgical procedures remain possible. This confirms 
the observation of McOuade et al20, that the use of covered stents in SFA occlusive 
disease is not related to an increased amputation rate, due to the covering of collaterals, 
in case of failure. These results are also supported by Doomernik et al23 • Chapter 4 reveals 
that popliteal anatomy deteriorates after endograft failure. Still despite this, 75% of the 
patients needing secondary surgery could be treated with a AK bypass. Patency rates of 
these secondary procedures are 55% at 1 year. However, almost 25% of patients with a 
failed endograft could be treated conservatively and elude a surgical bypass completely. 
Endograft placement can therefore safely be seen as a bridge to surgery. 
In Chapter 6 two case reports show that after failure of a primary surgical bypass an 
endoluminal bypass can also be considered as a secondary procedure. Most important 
for the success of this procedure is a non hostile anatomy. Popliteal diameter and crural 
outflow vessels should be of good quality. Major advantage of an endograft as secondary 
procedure is prevention of redo surgery, which is associated with higher morbidity 
rates24-28• 
• 
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Future perspectives 
In the near future, long term patency rates, two years and up, of the first heparin-bonded 
endografts will follow. Most interesting will be to see if the endograft can match the 
excellent four year patency rates of the venous bypass. Primary patency rates might 
possibly be lower than that of the autologous venous bypass, as endoluminal techniques 
usually require more re-interventions to prolong patency. The number of re-interventions 
needed for maintaining endograft patency will be of the utmost importance as this will in 
part define the role of endografts in the future. 
Our group is currently describing a cost analysis comparing endografts with surgical bypass. 
On a background of increasing costs for health care, we believe a realistic comparison 
of the costs is necessary. Although placement of an endograft is more expensive than 
placement of a venous surgical bypass, our theory is that the shorter hospital admittance, 
lower complication rate and possibly shorter operating theatre time will compensate for 
the price of the endograft. Primarily we are evaluating short term (<30 day) costs, but in 
the future we will expand to long term cost comparison. In this comparison the number 
of re-interventions needed for endograft patency will be evaluated as this is usually seen 
as a major cost factor. In our series, as described in Chapter 3, only 4 (7 .1 %) PT A's (2 with 
stent placement) were necessary in 56 treated limbs to prevent failure. So perhaps long 
term costs of the endograft will also be comparable to those of the surgical bypass. 
In recent studies describing results of the endograft one-year primary patency rates varied 
between 44% and 95%29·30. The antithrombogenic strategy, among other things, greatly 
differed between these studies. In most series patients were treated with acetylsalicylic 
acid while in half of them clopidogrel was added for 6 weeks to over 3 months. In a study 
focusing on patients with a popliteal artery aneurysm, treated with an endograft, it was 
shown that the use of clopidogrel was the only predictor for outcome31 emphasizing the 
importance of proper medical treatment. Based on this series, and extrapolated from 
the DES in cardiology we treat our patients with clopidogrel for one year. Future studies 
should further describe best medical treatment after placement of endografts. 
In synthetic surgical bypasses heparin bonding improved patency rates to the level of 
the venous bypass (69-81 % at two years). Recent developments have combined the 
technique of heparin bonding with endografts. These developments could increase 
patency rates. We commenced a prospective randomized controlled trial, the SUrgical 
versus PERcutaneous Bypass (SuperB, NCT01220245) as described in Chapter 8. The 
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aim of this randomized tria l  is two-fold.  F irst, it compares patency rates of the endograft 
with the cu rrent gold standard ,  the venous femoropopl itea l  bypass. Secondly, it a ims to 
demonstrate that an endovascu la r  approach is associated with fewer compl ications and 
thus an improved qua l ity of l ife. We bel ieve that with in the fra i l  vascu lar  popu lation this 
Ool is important.  Our SuperB tria l  hypothesizes that the treatment of long lesions of the 
SFA with a heparin-bonded endograft wil l show comparable patency rates compared to 
the surgica l bypass, but a better qua l ity of l ife, re lated to reduced morbid ity. 
It wou ld a lso be interesting to compare endograft placement to other  min ima l  invasive 
procedu res, such as the remote endarterectomy. Comparative stud ies such as these, 
assessing both patency and qua l ity of l ife, a re essentia l  in defin ing the role of heparin­
covered stent-grafts i n  the treatment a lgorithm of chronic occlusive SFA d isease. 
General conclusion 
Based on our studies we have shown that the use of heparin-bonded covered stents for 
long ch ronic occlusions of the SFA is feasible, safe and approaches patency rates with in 
the range of surg ica l venous reconstruction .  Th is ind icates that the use of heparin-bonded 
stent-grafts might be a viable a lternative for surgery in a specific group of patients. 
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Algemene discussie 
Sinds de ontdekking van de veneuze femoropopliteale bypass door Jean Kunlin in 1948, 
is het de gouden standaard voor lange vernauwende afwijkingen van de arteria femoralis 
superficialis (AFS)1 • Recente technologische ontwikkelingen hebben de endoluminale 
technieken toegevoegd aan het scala aan behandelopties voor chronisch oblitererend 
perifeer vaatlijden. In de vorige hoofdstukken hebben we geprobeerd de precieze rol van 
deze relatief nieuwe behandelmodaliteit te omschrijven. 
Natuurlijk bestaat de primaire behandeling van perifeer vaatlijden uit optimale 
medicamenteuze behandel ing2•3 • Thrombocytenaggregatieremmers and statines dienen 
vanaf de eerste presentatie van symptomen gestart te warden. Patienten die zich 
presenteren met claudicatio intermittens (Cl) hebben bewezen baat bij gesuperviseerde 
looptraining4·6. Wanneer deze conservatieve behandeling onvoldoende resultaat geeft, 
kan er bij patienten met Rutherford classificatie 3 t/m 6 besloten warden tot operatief 
ingrijpen. Bij de keuze tot chirurgische behandeling is voor lange laesies van de AFS de 
autologe veneuze bypass nog steeds de gouden standaard7 . Deze bypass kent primaire 
patencies van 75% na vijf jaar follow-up8·9 • Helaas is chirurgische reconstructie gerelateerd 
aan een h oge kans op morbiditeit, in het bijzonder op vroege postoperatieve complicaties 
zoals wondgenezingsstoornissen (5-44%)9• 1 0 en oedeem (40-100%)1 1 • 1 2 . Uiteindelijk faalt 
10 tot 20% van de chirurgische bypass binnen 1 jaar13 (respectievelijk autoloog veneus 
en kunststof bypass). 
Endoluminale technieken kunnen een rol spelen in zowel de primaire behandeling 
van perifeer vaatlijden als de secundaire behandeling (Hoofdstuk 2, Hoofdstuk 6). 
Percutane transluminale angioplastiek (PTA) is voor korte laesies van de AFS reeds de 
eerste behandeloptie1 . Bij endoluminale behandeling van lange laesies van de AFS 
(> 10cm) wordt het plaatsen van een stent aanbevolen 1 4-1 6• Om in-stent re-stenosen, door 
neo-intima hyperplasie, bij TASC-II C/D laesies te voorkomen, worden deze bij voorkeur 
behandeld met een gecoverde nitinol stent. Gecoverde stents beperken het voorkomen 
van re-stenosen tot rand-stenosen1 7 , welke makkelijker te behandelen zijn. Verscheidene 
studies beschrijven een verbetering van patency van 70%1 4-1 6 naar 83%18• 1 9 bij gebruik van 
gecoverde stents. De niet heparine-gebonden endografts hebben primaire patencies die 
vergelijkbaar zijn met die van de kunststof chirurgische bypass (2-jaar primaire patency 
63% vs 64 % voor de bypass20) .  
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De keuze vooreen endoluminale bypass heeft verschillende voordelen. Het is een minimaal 
invasieve behandeloptie in een vaak kwetsbare populatie. Er is geen grote chirurgie voor 
noodzakelijk. Endografts kunnen percutaan geplaatst worden of via een kleine inguinale 
incisie. Deze ingreep kan onder lokale anesthesie gebeuren. Het minimaal invasieve 
karakter van de endograft plaatsing vertaalt zich in een lage morbiditeit. Zoals beschreven 
in hoofdstuk 3, was onze algemene complicatie risico 7 .5%. In onze patientenpopulatie 
waren er geen wondgenezingsstoornissen en slechts 1 patient ontwikkelde postoperatief 
oedeem. Een ander voordeel van de endograft is het snelle postoperatieve herstel. 
Na een autologe veneuze femoropopliteale bypass zijn patienten gemiddeld 5 dagen 
opgenomen (4.4-9 . 1  dagen21 •22} .  Onze patienten waren gemiddeld minder dan 3 dagen 
opgenomen en er waren geen opnamedagen op de intensive care (Hoofdstuk 3). 
Primair kiezen voor het plaatsen van een endograft voorkomt chirurgische interventies 
in 89% van de totale patientenpopulatie, door of patency van de endograft, of klinische 
verbetering ondanks falen van de endograft (na 2 jaar follow-up, Hoofdstuk 4). En mocht 
er na falen van de endograft een indicatie zijn tot behandeling dan is het secundair 
plaatsen van een autologe veneuze bypass nog mogelijk, omdat de endograft de 
eventueel aanwezige vena saphena magna (VSM) behoudt. 
Hetverliesvan collateral en wordtvaak gezien als nadeel van het plaatsenvan een gecoverde 
stent. Het overstenten van collateralen zou de kliniek van de patient verslechteren, 
wanneer de stent occludeerd. In hoofdstuk 4 en 5 beschrijven wij de klinische uitkomst van 
patienten na occluderen van de endograft. In onze populatie keerden de meerderheid 
van de patienten, na falen van de endograft, terug naar hun oude of een verbeterde 
niveau (43% verbeterde Rutherford classificatie, 37% gelijke Rutherford classificatie). De 
kans op amputatie na falen was zeer klein (0-6%) en secundaire chirurgische ingrepen 
bleven mogelijk. Deze cijfers bevestigen de observaties zoals beschreven door McOuade 
et al22, dat het gebruik van gecoverde stents niet leidt tot een hoger amputatie risico na 
falen van de stent. Ook Doomernik et al23 onderschrijven onze resultaten. 
In hoofdstuk 4 laten we zien dat de anatomie van de arteria poplitea (AP) verslechterd na 
falen van de endograft. Ondanks deze observatie kon 75% van de patienten behandeld 
worden met een supragenuale bypass. De patency voor deze secundaire procedures was 
55% na 1 jaar. Daarentegen kan een kwart van de patienten na falen van de endograft 
conservatief behandeld worden en zo chirurgie volledig omzeilen. Het plaatsen van een 
endograft kan daarom gezien worden als een brug naar chirurgie. 
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In hoofdstuk 6 laten twee case reports zien dat na fa len van een primair  ch i ru rg ische 
bypass, een endolumina le  bypass ook a ls secundaire behandel ing gebru ikt kan worden . 
De belangrijkste voorwaa rde voor het succes van deze ingreep is een gesch ikte anatomie.  
De d iameter van de AP en de crura le vaten dienen van goede kwa l iteit te zijn .  Het 
grootste voordeel van een endograft a l s  secundaire procedu re is het voorkomen van 
redo-ch irurgie, wel ke geassocieerd is met hoge morbid iteit24-28• 
Toekomstperspectieven 
Binnenkort zu l len de lange termijns resu ltaten (meer dan 2 jaar) van de eerste heparine­
gebonden endografts volgen . Het za l interessant zijn om te zien of deze vergel ijkba re 
patencies heeft met de zeer goede 4-jaars resultaten van de veneuze bypass. De primaire 
patency zou lager kunnen u itkomen dan die van de autologe veneuze bypass, aangezien 
voor endolumina le technieken vaak  meer re-interventies noodzake l ijk  zijn om de patency 
te behouden. Het aanta l re-interventies dat noodzakel ijk  is za l zeer be langrijk zijn om de 
rol van endografts te bepa len .  
Op d it moment voeren wij een kosten ana lyse u it waarbij we het gebru ik  van de 
endograft vergel ijken met de ch i ru rg ische bypass. Met de toenemende kosten i n  
de gezondheidszorg vinden wij een  rea l i stische vergel ijk ing van  de kosten be langrijk .  
Hoewel het p laatsen van een endograft duurder is dan het p laatsen van een veneuze 
bypass, verwachten wij dat de kortere opnameduur, het l agere aantal compl icaties en de 
kortere operatiedu u r  compenseren voor de kosten van de stent. Prima i r  zu l len we ons 
focussen op de korte termijn kosten (<30 dagen), maa r in  de toekomst zu l len  we ook 
de langere term ijn  kosten vergel ij ken .  Ook h ier za l het aanta l  re-interventies weer van 
be lang zijn,  aangezien dat vaak  gezien wordt a ls grote kosten factor. I n  onze serie, zoa ls  
beschreven in  hoofdstuk 3 ,  waren er  maar  4 PTA's noodzake l ij k  (7  . 1  %)  om 56 endografts 
patent te houden . Dus ook op de l ange termijn kunnen de kosten vergel ijkbaar  zijn met 
d ie  van een ch i rurg ische bypass. 
I n  recente stud ies varieerde de prima i re patency van de endograft tussen de 44% en 
95%29•30. Er was tussen deze studies een grote variatie i n ,  onder andere, de gebru ikte 
postoperatieve medica menteuze thera pie.  In de meeste series werden patienten 
postoperatief behandeld met acetylsa l icylzuu r, in de helft van de geva l len gecombineerd 
met clopidogre l  (gedurende 6 weken tot 3 maanden). In een stud ie  aangaande patienten 
d ie  behandeld waren met een endog raft voor een popl iteaa l  aneurysma,  was het gebru ik  
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van clopidogrel de enige variabele met een positief voorspellende waarde voor een 
goede uitkomst31 . Hiermee werd de noodzaak tot goede medicamenteuze behandeling 
nogmaals onderstreept. Gebaseerd op deze serie, en ge-extrapoleerd van de drug­
eluting stents (DES) vanuit de cardiologie, behandelen wij onze patienten met clopidogrel 
gedurende 1 jaar. Toekomstige studies zullen de optimale medicamenteuze therapie na 
endograft plaatsing moeten onderzoeken. 
In kunststof chirurgische bypasses heeft de introductie van heparine-binding de 
patency verbeterd tot het niveau van de veneuze bypass (69-81 % na 2 jaar). Recente 
ontwikkelingen hebben de techniek van de heparine-binding gecombineerd met de 
endografts. Deze ontwikkelingen kunnen de patency van endograft mogelijk ook 
verbeteren. Daarom hebben wij een prospectieve, gerandomiseerde studie opgezet, 
de 'SUrgical versus PERcutaneous Bypass' (SuperB, NCT01220245), zoals beschreven in 
hoofdstuk 8. Het doel van deze gerandomiseerde trial is tweeledig. Allereerst zullen we 
de patency vergelijken van de endograft en de huidige gouden standaard, de autologe 
veneuze femoropopliteale bypass. Ten tweede willen we aantonen dat een endoluminale 
bypass geassocieerd is met minder complicaties en een betere kwaliteit van !even (Ool). 
We vinden dat in de kwetsbare vaatpopulatie deze Ool belangrijk is. De hypothese 
van onze SuperB trial is dat de behandeling van lange laesies van de AFS middels een 
endograft leidt tot een vergelijkbare patency als die van de chirurgische bypass , maar 
met een betere kwaliteit van !even, gerelateerd aan minder complicaties. 
Het zou ook interessant zijn om de endograft te vergelijken met andere minimaal 
invasieve technieken zoals de remote endarterectomy (REA). Vergelijkende studies , zoals 
de SuperB trial, die zowel patency als Ool beschrijven, zijn noodzakelijk om de rol van 
heparine-gebonden endografts in de behandeling van chronisch perifeer vaatlijden van 
de AFS, te bepalen. 
Algemene conclusie 
Gebaseerd op onze studies hebben we laten zien dat het gebruik van heparine-gebonden 
endografts voor lange laesies van de AFS een haalbare en veilige behandeloptie is , met 
patencies die die van de veneuze bypass benaderen. Dit kan betekenen dat het gebruik 
van een heparine-gebonden endograft een goed alternatief is voor chirurgie in een 
specifieke patientenpopulatie. 
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